The Use of Bellafill for Atrophic Acne Scar Correction in the Full Facial Area
Phase: NA
Conditions: Atrophic Acne Scarring
Sponsor: Suneva Medical, Inc.

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 1 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
 
 
 
PROTOCOL 
 
 
The Use of Bellafill® for Atrophic Acne Scar Correction 
in the Full Facial Area 
 
 
 
Protocol Number: SUN-15-04 
Version 1.0 (28-Aug-2015) 
 
 
 
Study Sponsor: 
Suneva Medical, Inc. 
5383 Hollister Ave., Suite 100 
Santa Barbara, CA 93111 
805-845-0020 
 
Contract Research Organization: 
ethica CRO Inc. 
8555 Transcanada Hwy, Suite 201 
Montreal, Quebec, H4S 1Z6 
866-384-4221 
 
 
CONFIDENTIAL 
The information contained within this clinical study protocol 
and the resulting data are considered confidential by Suneva Medical, Inc. and 
cannot be disclosed or reproduced without expressed written permission. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 2 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
PROTOCOL APPROVAL PAGE 
 
 
The following individuals approve this version of Protocol #SUN-15-04. All changes 
to this version of the protocol must have prior written approval and require an 
amendment or administrative letter. 
Suneva Representative: 
Jwala Karnik MD, Chief Medical Officer 
Signature:  
 
Date:   
 
ethica CRO Representative: 
Murray Jensen, MSc 
Director of Clinical and Scientific Affairs 
Signature:  
 
Date:   
 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 3 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
INVESTIGATOR SIGNATURE PAGE 
 
 
I agree to: 
 Implement and conduct this study diligently and in strict compliance with the protocol, 
ICH-GCP Guidelines, and all applicable laws and regulations. 
 Maintain all information supplied by the Sponsor or its designate in confidence and, 
when this information is submitted to an Institutional Review Board (IRB) or another 
group, it will be submitted with a designation that the material is confidential. 
 
 
 
I have read this protocol in its entirety and I agree to all aspects. 
 
 
 
 
Investigator Printed Name 
Signature 
Date 
Investigator Printed Name 
Signature 
Date 
Investigator Printed Name 
Signature 
Date 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 4 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
TABLE OF CONTENTS 
PROTOCOL APPROVAL PAGE ..................................................................................................................... 2 
INVESTIGATOR SIGNATURE PAGE ............................................................................................................. 3 
GLOSSARY OF ABBREVIATIONS ................................................................................................................. 6 
PROTOCOL SYNOPSIS ................................................................................................................................. 7 
1. 
BACKGROUND AND RATIONALE ....................................................................................................... 10 
1.1 
Incidence and Severity of Acne Scarring ........................................................................... 10 
1.2 
Bellafill for the Correction of Acne Scarring ....................................................................... 11 
1.3 
Alternative Treatments for Acne Scars .............................................................................. 11 
1.4 
Current Clinical Study ........................................................................................................ 11 
2. 
STUDY OBJECTIVE ............................................................................................................................. 11 
3. 
STUDY DESIGN.................................................................................................................................... 12 
4. 
STUDY POPULATION .......................................................................................................................... 12 
4.1 
Number of Subjects ........................................................................................................... 12 
4.2 
Study Population Characteristics ....................................................................................... 12 
4.3 
Inclusion Criteria ................................................................................................................ 12 
4.4 
Exclusion Criteria .............................................................................................................. 12 
5. 
METHODS ............................................................................................................................................ 13 
5.1 
Treatment .......................................................................................................................... 13 
5.2 
Treatment Area ................................................................................................................. 14 
5.3 
Touch-up Treatment .......................................................................................................... 15 
5.4 
Prohibited Treatment/Procedures ...................................................................................... 15 
6. 
MATERIALS .......................................................................................................................................... 16 
6.1 
Packaging and Labeling .................................................................................................... 16 
6.2 
Treatment Regimen/Volume Allowances ........................................................................... 16 
6.3 
Supplies and Accountability ............................................................................................... 16 
6.4 
Other Study Supplies ........................................................................................................ 16 
7. 
STUDY METHODS AND PROCEDURES ............................................................................................. 16 
7.1 
Informed Consent and Subject Privacy ............................................................................. 16 
7.2 
Procedures for Final Study Entry ....................................................................................... 16 
7.3 
Subject Identification and Treatment Allocation ................................................................. 17 
7.4 
Blinding ............................................................................................................................. 17 
8. 
EFFICACY ASSESSMENTS ................................................................................................................. 17 
8.1 
Photography ...................................................................................................................... 17 
9. 
SAFETY ASSESSMENTS ..................................................................................................................... 17 
10. SCHEDULE OF STUDY ACTIVITIES ................................................................................................... 17 
10.1 
Assessment Schedule ..................................................................................................... 18 
10.2 
Study Procedures ............................................................................................................ 18 
10.2.1 
Visit 1: Screening Visit (Month -1) ............................................................................ 18 
10.2.2 
Visit 2:  Treatment Visit (D0) .................................................................................... 19 
10.2.3 
Visit 3 (M1) ........................................................................................................................19 
10.2.4 
Visit 4 (M4) ........................................................................................................................19 
10.2.5 
Visit 5 (M7) ........................................................................................................................19 
10.3 
Instructions for Subjects ................................................................................................... 20 
10.4 
Unscheduled Visits .......................................................................................................... 20 
10.5 
Early Discontinuation/Withdrawal ..................................................................................... 20 
10.6 
Lost to Follow-Up ............................................................................................................. 20 
10.7 
Study Termination ............................................................................................................ 21 
11. ADVERSE EVENTS ............................................................................................................................. 21 
11.1 
Definitions ........................................................................................................................ 21 
11.1.1 
Adverse Events (AEs) .............................................................................................. 21 
11.1.2 
Common Treatment Responses (CTRs) .................................................................. 22 
11.1.3 
Serious Adverse Events and Unexpected Adverse Device Effects ................................... 22 
11.1.4 
Severity ................................................................................................................... 22 
11.1.5 
Relationship to Study Device ................................................................................... 22 
11.2 
Procedures for Reporting Adverse Events ....................................................................... 23 
11.3 
Procedures for Unmasking of Study Devices ................................................................... 23 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 5 of 60 
(v1.0; 28-Aug-2015) 
 
 
11.4 
Pregnancy ....................................................................................................................... 23 
12. STATISTICS ......................................................................................................................................... 23 
12.1 
Sample Size Justification ................................................................................................. 23 
12.2 
Efficacy Parameter Analysis ............................................................................................ 23 
12.3 
Safety Analysis ................................................................................................................ 24 
13. ADMINISTRATIVE ISSUES .................................................................................................................. 24 
13.1 
Protection of Human Subjects.......................................................................................... 24 
13.1.1 
Compliance with Informed Consent Regulations (21 CFR Part 50) .................................. 24 
13.1.2 
Compliance with Institutional Review Board Regulations (21 CFR Part 56) ..................... 24 
13.1.3 
Compliance with the ICH-GCP Guidelines (ICH E6) ................................................ 24 
13.2 
Changes to the Protocol .................................................................................................. 24 
13.3 
Subject Confidentiality and Privacy .................................................................................. 25 
13.4 
Required Regulatory Documents ..................................................................................... 25 
13.4.1 
Source Documents .................................................................................................. 25 
13.4.2 
Electronic Case Report Form (eCRF) Completion ................................................... 25 
13.4.3 
Study Summary ....................................................................................................... 26 
13.4.4 
Retention of Documentation .................................................................................... 26 
13.5 
Monitoring by the Sponsor ............................................................................................... 26 
13.6 
On-Site Audits .................................................................................................................. 26 
13.7 
Proprietary Information .................................................................................................... 26 
13.8 
Publications ..................................................................................................................... 27 
13.9 
References ...................................................................................................................... 27 
APPENDICES ............................................................................................................................................... 28 
APPENDIX 1:  STUDY ASSESSMENTS ...................................................................................................... 29 
APPENDIX 3:  SKIN TEST INSTRUCTIONS FOR USE ............................................................................... 31 
APPENDIX 3:  BELLAFILL INSTRUCTIONS FOR USE................................................................................ 37 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 6 of 60 
(v1.0; 28-Aug-2015) 
 
 
GLOSSARY OF ABBREVIATIONS 
 
 
AE 
Adverse Event 
ASAS 
Acne Scar Assessment Scale 
CFR 
U. S. Code of Federal Regulations 
eCRF 
Electronic Case Report Form 
CRO 
Contract Research Organization 
CTR 
Common Treatment Responses 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practices 
HIPAA 
Health Insurance Portability and Accountability Act 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonization 
IRB 
Independent Review Board 
ITT 
Intent to Treat 
NSAID 
Non-steroidal anti-inflammatory drug 
PGAIS 
Physician Global Aesthetic Improvement Scale 
PMMA 
Polymethylmethacrylate 
QoL 
Quality of Life 
SAE 
Serious Adverse Event 
SAS 
Statistical Analysis Software 
SDs 
Source Documents 
SGAIS 
Subject Global Aesthetic Improvement Scale 
UADE 
Unanticipated Adverse Device Effects 
UPT 
Urine Pregnancy Test 
WOCBP 
Women of Child Bearing Potential 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 7 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
PROTOCOL SYNOPSIS 
 
Title 
The Use of Bellafill® for Atrophic Acne Scar Correction in the Full Facial Area 
Study Device 
Bellafill® 
Study Objective 
To demonstrate the safety and efficacy of Bellafill for the correction of 
distensible atrophic acne scars in the full facial area. 
Study 
Population 
Male and female subjects >21 years of age with at least 4 distensible atrophic 
acne scars located in the full facial area that, in the Investigator’s opinion, are 
correctable. 
Study Design 
Open-label, multicenter, prospective pilot study. 
Number of Sites 
Approximately 10 sites. 
Number of 
Subjects 
Approximately 50 subjects. 
Treatment 
Groups 
All subjects will receive treatment with Bellafill. 
Duration of 
Study 
The duration of the study is approximately 8 months. 
Inclusion 
Criteria 
1. Outpatient, male or female subjects of any race, 21 years of age or older. 
Female subjects of childbearing potential must have a negative urine 
pregnancy test result at Baseline and practice a reliable method of 
contraception throughout the study. 
2. Negative response to the Bellafill Skin Test. 
3. Presence of ≥4 distensible atrophic acne scars (treatment scars) in in the 
facial area. 
4. Subject desires correction of his/her atrophic acne scarring. 
5. All Fitzpatrick skin types are eligible. 
6. Willing to withhold additional aesthetic therapies to the proposed 
treatment area (e.g., other soft tissue fillers such as hyaluronic acid, 
and/or any resurfacing procedures (as described in Protocol Section 5.4) 
for the duration of the study. 
7. Able to follow study instructions and likely to complete all required visits, 
as assessed by the Investigator. 
8. Sign an IRB-approved Informed Consent Form, Photographic Release 
Form, and the Authorization for Use and release of Health and Research 
Study Information (HIPAA) Form prior to any study-related procedures 
being performed. 
Exclusion 
Criteria 
1. Female subjects that are pregnant (positive urine pregnancy test), breast- 
feeding, or who are of childbearing potential and not practicing a reliable 
method of birth control. 
2. Undergone facial treatments with any prohibited treatment/procedures 
and/or use of any other prohibited treatment/procedure within certain time 
periods as listed in Protocol Section 5.4. 
3. Excisional facial surgery (such as Blepharoplasty, Face Lift, Rhinoplasty) 
of the face less than 6 months prior to study enrollment or plans for facial 
surgery during the study. 
4. History of bleeding disorders. 
5. Presence of any skin pathology or condition that could interfere with the 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 8 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
evaluation of the treatment areas, worsen due to the proposed treatment 
or require interfering topical, systemic or surgical therapy. 
6. Recent or current history of inflammatory skin disease, infection, 
cancerous/pre-cancerous lesion, unhealed wound or clinically significant 
acne in the proposed treatment areas. Clinically significant acne is 
defined as a patient whom has >3 active inflammatory acne lesions in the 
treatment areas. 
7. History of systemic granulomatous diseases active or inactive (e.g., 
Sarcoid, Wegeners, TB) or connective tissue diseases (e.g., lupus, 
dermatomyositis). 
8. Hypertrophic acne scars, any evidence of keloid scarring in the treatment 
area. 
9. Known hypersensitivity or previous allergic reaction to any of the 
components of the study device (including lidocaine or any amide-based 
anesthetic), or has a history of allergies to any bovine collagen products, 
including but not limited to injectable collagen, collagen implants, 
hemostatic sponges, and collagen-based sutures. 
10. Undergone or be planning to undergo desensitization injections to meat 
products. 
11. Unable to communicate or cooperate with the Investigator due to a 
language barrier (non-English speaking), poor mental development, or 
impaired cerebral function. 
12. Evidence of alcohol or drug abuse (Investigator opinion), or history of 
poor cooperation, non-compliance with medical treatment, or unreliability. 
13. Use of an investigational device, biologic or drug in the past 30 days, or 
be currently participating in an experimental drug, biologic or device trial. 
14. Exhibits additional physical attributes which prevent the assessment or 
treatment of the atrophic scars, as judged by the Investigator, such as 
excessive hair, traumatic or surgical scars, excessive hyperpigmentation 
in the treatment area, etc. 
15. Has a condition or be in a situation that, in the Investigator's opinion, may 
put the subject at significant risk, may confound the study results, or may 
interfere significantly with the subject's participation in the study. 
16. An employee (or a relative of an employee) of the Investigator, Sponsor 
or representative of the Sponsor. 
Study 
Measurements 
Effectiveness: 
• 
Acne Scar Assessment Scale (ASAS): a validated 5-point static scale 
assessing physician impression of acne scar severity. 
• 
Physician Global Aesthetic Improvement Scale (PGAIS): a 5-point 
dynamic scale assessing cosmetic improvement. 
• 
Subject Global Aesthetic Improvement Scale (SGAIS): a 5-point dynamic 
scale assessing cosmetic improvement. 
• 
Subject QOL Impact Scale: (33 questions): a 33-question survey that 
allows the subject to specifically address how acne scarring has affected 
his/her emotional and functional status. 
Safety: 
• 
Adverse events: rate of AEs, type of AEs, relationship of AEs to Bellafill. 
Study 
Procedures 
All enrolled subjects will receive an initial treatment with Bellafill, and will also 
receive  a  touch-up  treatment  if  necessary  to  achieve  optimal  correction. 
Investigator  assessments,  subject  assessments,  and  photography  will  be 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 9 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
used to evaluate the effectiveness of the treatment. Subjects will be 
evaluated at the following time points: Screening (Month -1), Day 0 
(Baseline), Month 1, Month 4, and Month 7. 
Sample Size 
Justification 
This is an exploratory study and a formal sample size justification is not 
provided. It is the opinion of the Sponsor that a total of 50 subjects will be 
sufficient to achieve the objectives of the study. 
Statistical 
Methods 
Statistical analyses will be conducted on an ITT basis (i.e., all enrolled 
subjects that have fully passed screening and have received initial treatment 
with Bellafill will be included in the analyses). Descriptive statistics  (i.e., 
mean, standard deviation, etc.) will be provided for all continuous variables 
and frequencies for all categorical variables collected in this study. When 
appropriate, exploratory inferential statistical analyses will be conducted using 
SAS® software (9.3 or higher). Comparisons of interest will be performed 
using parametric or non-parametric testing, as appropriate. The level of 
significance will be fixed at 0.05. No adjustments for multiplicity will be 
performed. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 10 of 60 
(v1.0; 28-Aug-2015) 
 
 
1. 
Background and Rationale 
Acne scars occur when acne lesions become large enough that the amount of localized 
inflammation overcomes the skin’s ability to heal normally. Dermal collagen is damaged 
and resorbed, leaving defects that are manifested as depressions in the skin surface. 
Acne scarring can have significant impact on well-being and quality of life, especially for 
people with acne scarring. The presence of acne scars on a person’s face can be 
aesthetically unappealing leading to negative social consequences. 
 
There are two general categories of Acne Scars:1 
Atrophic or depressed 
Depressions and valleys in the skin with resulting 
shadowing 
Hypertrophic or raised 
Firm, raised papules or nodules on the skin 
 
Typically, over 90% of the U.S. population experiences the onset of acne during puberty 
and teen years2 with some women experiencing episodes in the late 20’s through their 
40’s due to hormonal changes.3 A significant percentage will go on to have long term or 
extensive acne scarring,1 90% of which are atrophic acne scars and the remaining 10% 
hypertrophic or some mix of both scars.4 The most commonly used descriptors for 
atrophic scars fall into the following categories.5 
• 
Ice Pick - Deep, narrow sharply marginated scars which resemble how the skin 
might look if injured with an ice pick. 
• 
Rolling or Distensible - More superficial scars with rolled edges that blend more 
gently into surrounding normal skin. 
• 
Boxcar - Sharply marginated depressions with a flat bottom, broader than Ice 
Pick scars. 
 
1.1 
Incidence and Severity of Acne Scarring 
There is no definitive source of data that clearly shows how many people are afflicted 
with each type of scar in the U.S. However, based on the few published studies found in 
the peer-reviewed literature and following discussions with our clinical advisors, Suneva 
Medical Inc. has developed a general picture of how many people are afflicted. 
 
With regard to scar type, between 60 to 75% of the people with acne scars will have a 
form of rolling or distensible scar as their predominant scar type with roughly 5 to 10% 
having mostly boxcar scars. The remaining 15 to 20% will have ice pick scars as their 
most common scar finding.6 Most individuals with acne scarring will have a mixture of 
two or more types of depressed scars. 
 
Severity is challenging to define due to irregularities in the scar depression as well as the 
large range in the shape and size of acne scars. In general, studies suggest that mild 
scarring occurs in roughly 60 to 70% of people with scars, moderate scarring occurs in 
15 to 25% and 5 to 15% of people with scars suffer from severe scarring.7 
 
Some clinicians believe that people between the ages of 35 to 55 have a higher 
incidence of moderate acne scarring due to the limited medical treatments for acne 
available 25 years ago.8 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 11 of 60 
(v1.0; 28-Aug-2015) 
 
 
1.2 
Bellafill for the Correction of Acne Scarring 
Based on a pivotal double-blinded, randomized, placebo-controlled study, the FDA 
approved Bellafill for the correction of acne scars in December 2014. 
 
The study required a high threshold for success in which the primary effectiveness 
endpoint was proven superior for subjects treated with Bellafill compared to Control at 6 
months. At 6 months, the response rate for Bellafill was 64% vs. 33% for Control 
(p=0.0005). Bellafill continued to show effectiveness by an unblinded assessment at 12 
months (71%). A responder was defined as a subject who had 50% or more of treated 
acne scars improve by two or more points on a validated 4-point Acne Scar Rating Scale 
(ASRS). 
 
Secondary effectiveness endpoints were evaluated, where both Investigators and 
subjects were asked to evaluate appearance on a Global Aesthetic Improvement Scale 
that was blinded through 6 months and unblinded at 12 months. On the Physician Global 
Aesthetic Improvement Scale (PGAIS), 84% of subjects were rated as improved at 6 
months and 98% were improved at 12 months by an unblinded assessment. On the 
Subject Global Aesthetic Improvement Scale (SGAIS), 77% of subjects rated their 
appearance as improved at 6 months and 83% rated their appearance as improved at 
12 months. 
 
1.3 
Alternative Treatments for Acne Scars 
Treatments for acne scarring include chemical peels, dermabrasion (including 
microdermabrasion and traditional dermabrasion), laser resurfacing (ablative and non- 
ablative), microneedling, dermal fillers, and surgery (i.e., punch excisions). Resurfacing 
techniques, such as chemical peels, dermabrasion or laser resurfacing are designed to 
lower the level of the skin surrounding the scar as well as induce new collagen formation 
(i.e., these techniques match the surrounding skin to the depression of the scar). These 
treatments require wounding or damaging relatively large areas of healthy skin on the 
face, typically resulting in considerable patient discomfort and extended healing time. 
The more aggressive forms of resurfacing, such as ablative laser treatments or rotary 
dermabrasion, carry risks of pain, infection, pigmentary changes and further scarring. 
Milder resurfacing techniques, such as microdermabrasion and superficial chemical 
peeling, are usually not substantially effective. Microneedling relies on the principle of 
collagen stimulation that may occur as a result of the release of growth factors following 
needle piercing of the stratum corneum. While the skin is damaged to a lesser degree 
than resurfacing techniques, allowing for a faster recovery time, efficacy is limited with 
more severe grades of scars. Surgical treatments for acne scarring, such as punch 
excision, may also be employed. 
 
1.4 
Current Clinical Study 
The current pilot study of Bellafill will evaluate the efficacy and safety of Bellafill as an 
injectable filler for the correction of distensible atrophic acne scars in the full facial area. 
Depending on the diversity of study population demographics, exploratory analyses  
may be conducted to compare various subgroups and stratifications as well as 
investigate correlations between the various efficacy outcomes. 
 
2. 
Study Objective 
To demonstrate the safety and efficacy of Bellafill for the correction of distensible 
atrophic acne scars. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 12 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
3. 
Study Design 
This is an open-label, multicenter, prospective pilot study assessing the efficacy and 
safety of Bellafill for correction of distensible atrophic acne scars in the full facial area. 
All enrolled subjects will receive initial treatment with Bellafill, as well as touch-up 
treatments (if necessary to achieve optimal correction). Subjects will be evaluated at 
Screening (Month -1), Day 0 (Baseline) Month 1, Month 4, and Month 7. 
 
4. 
Study Population 
4.1 
Number of Subjects 
Approximately 50 male and/or female subjects 21 years of age or older who meet the 
protocol’s eligibility requirements will be enrolled in the study at approximately 10 
investigational sites. 
 
4.2 
Study Population Characteristics 
Subjects desiring correction of their acne scarring with an injectable dermal filler will be 
recruited for this study. 
 
4.3 
Inclusion Criteria 
1. Outpatient, male or female subjects of any race, 21 years of age or older. Female 
subjects of childbearing potential must have a negative urine pregnancy test result at 
Baseline and practice a reliable method of contraception throughout the study. 
A female is considered of childbearing potential unless she is: 
- postmenopausal for at least 12 months prior to study treatment administration; 
- without a uterus and/or both ovaries; or 
- has been surgically sterile for at least 6 months prior to study treatment administration. 
Reliable methods of contraception are: 
- hormonal methods or intrauterine device in use >90 days prior to study treatment administration; 
- barrier methods plus spermicide in use at least 14 days prior to study treatment administration; or 
- vasectomized partner. 
[Exception: Female subjects of childbearing potential who are not sexually active will not be required to practice a 
reliable method of contraception. These subjects may be enrolled at the Investigator’s discretion if they are 
counseled to remain sexually inactive during the study or agree to use an approved method of contraception should 
they become sexually active and understand the possible risks in getting pregnant during the study.] 
2. Negative response to the Bellafill Skin Test. 
3. Presence of ≥4 distensible atrophic acne scars (treatment scars) in in the facial area. 
4. Subject desires correction of his/her atrophic acne scarring. 
5. All Fitzpatrick skin types are eligible. 
6. Willing to withhold additional aesthetic therapies to the proposed treatment area 
(e.g., other soft tissue fillers such as hyaluronic acid, and/or any resurfacing 
procedures (as described in Protocol Section 5.4) for the duration of the study. 
7. Able to follow study instructions and likely to complete all required visits, as 
assessed by the Investigator. 
8. Sign an IRB-approved Informed Consent Form, Photographic Release Form, and the 
Authorization for Use and release of Health and Research Study Information 
(HIPAA) Form prior to any study-related procedures being performed. 
 
4.4 
Exclusion Criteria 
1. Female subjects that are pregnant (positive urine pregnancy test), breast-feeding, or 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 13 of 60 
(v1.0; 28-Aug-2015) 
 
 
who are of childbearing potential and not practicing a reliable method of birth control. 
2. Undergone facial treatments with any prohibited treatment/procedures and/or use of 
any other prohibited treatment/procedure within certain time periods as listed in 
Protocol Section 5.4. 
3. Excisional facial surgery (such as Blepharoplasty, Face Lift, Rhinoplasty) of the face 
less than 6 months prior to study enrollment or plans for facial surgery during the 
study. 
4. History of bleeding disorders. 
5. Presence of any skin pathology or condition that could interfere with the evaluation of 
the treatment areas, worsen due to the proposed treatment or require interfering 
topical, systemic or surgical therapy. 
6. Recent or current history of inflammatory skin disease, infection, cancerous/pre- 
cancerous lesion, unhealed wound or clinically significant acne in the proposed 
treatment areas. Clinically significant acne is defined as a patient whom has ≥3 
active inflammatory acne lesions in the treatment areas. 
7. History of systemic granulomatous diseases active or inactive (e.g., Sarcoid, 
Wegeners, TB) or connective tissue diseases (e.g., lupus, dermatomyositis). 
8. Hypertrophic acne scars, any evidence of keloid scarring in the treatment area. 
9. Known hypersensitivity or previous allergic reaction to any of the components of the 
study device (including lidocaine or any amide-based anesthetic), or has a history of 
allergies to any bovine collagen products, including but not limited to injectable 
collagen, collagen implants, hemostatic sponges, and collagen-based sutures. 
10. Undergone or be planning to undergo desensitization injections to meat products. 
11. Unable to communicate or cooperate with the Investigator due to a language barrier 
(non-English speaking), poor mental development, or impaired cerebral function. 
12. Evidence of alcohol or drug abuse (Investigator opinion), or history of poor 
cooperation, non-compliance with medical treatment, or unreliability. 
13. Use of an investigational device, biologic or drug in the past 30 days, or be currently 
participating in an experimental drug, biologic or device trial. 
14. Exhibits additional physical attributes which prevent the assessment or treatment of 
the atrophic scars, as judged by the Investigator, such as excessive hair, traumatic 
or surgical scars, excessive hyperpigmentation in the treatment area, etc. 
15. Has a condition or be in a situation that, in the Investigator's opinion, may put the 
subject at significant risk, may confound the study results, or may interfere 
significantly with the subject's participation in the study. 
16. An employee (or a relative of an employee) of the Investigator, Sponsor or 
representative of the Sponsor. 
 
5. 
Methods 
5.1 
Treatment 
Correctable acne scars will be individually identified and only scars that the Investigator 
determines to be correctable will receive study treatment. All eligible scars within the 
treatment area will be treated. 
 
Bellafill should be injected using a standard tunneling technique whereby the filler is 
injected in a retrograde manner utilizing several passes until the scar reaches a desired 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 14 of 60 
(v1.0; 28-Aug-2015) 
 
 
level of correction. A touch-up treatment is allowed if additional treatment is required to 
achieve optimal correction. 
 
5.2 
Treatment Area 
There will be four “quadrants” of the face where treatment is allowed and grading will 
occur. The glabellar, nose and upper lip areas are not to be treated: 
• 
The glabellar “no treatment” zone is defined as the area between the mid-pupillary 
lines up to 2 cm above the highest point of the eyebrow. This area will not receive 
treatment; 
 The no treatment area of the nose extends from the nasal bridge (and is contiguous 
with the glabellar no treatment zone) to the nasal sill and laterally to the cheek; 
 The upper lip will be defined as the area from the vermillion border of the upper lip to 
the nasal sill superiorly and the nasolabial fold laterally; 
 The face is split at the midline of the forehead and the chin and where the nose 
meets the cheek, creating two halves. Each half is then divided into upper and lower 
quadrants by a line extending from the lateral canthus to the superior junction of the 
pinna and the cheek. 
 
Each quadrant will be graded individually and receive a separate grade. The no 
treatment zones of the glabella, nose and upper lip should be respected as they have 
been selected to maximize the safety of the subject. 
 
 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 15 of 60 
(v1.0; 28-Aug-2015) 
 
 
5.3 
Touch-up Treatment 
A “touch-up treatment” is permitted at study Visit 3 (Month 1). The Investigator will 
evaluate each lesion and determine if a treated scar is undercorrected and whether 
additional improvement could be obtained with a touch-up treatment. 
 
5.4 
Prohibited Treatment/Procedures 
Use of other soft tissue fillers in the face and/or concurrent administration of other 
aesthetic treatments of the face during the study is prohibited (e.g., lasers, implants, 
peels, microdermabrasion, etc.). Other necessary therapies that will not interfere with 
the response to treatment may be provided to the subject at the discretion of the 
Investigator. 
 
Use of the following medications/procedures (concurrent and contraindicated  
treatments) have either restrictions for usage, or are prohibited during the course of the 
study and appropriate wash-out periods noted below must be respected: 
 
Dermal Fillers used in the face or neck (including lips) 
▪▪ Hyaluronic acid 
o 
Juvederm, Restylane, Belotero ….…….……… 
12 months prior to BL Visit 
o 
Voluma, Restylane Lyft ……………….………… 12 months prior to BL Visit 
Hydroxylapatite…………………….…………………..…….. 24 months prior to BL Visit 
Polylactic acid………………………………………………... 24 months prior to BL Visit 
Porcine or human collagen 
Autologous fat 
12 months prior to BL Visit 
Bellafill 
Prohibited Treatment: Any past use of a permanent filler or implant outside of Bellafill 
(e.g., polyacrylamide, polyethylene oxide, silicone) 
▪▪ 
▪▪ 
▪▪ 
▪▪ 
▪▪ 
Systemic Medications 
▪▪ Accutane…………………………………………….. 
12 months prior to BL Visit 
▪▪ Corticosteroiods (e.g., prednisone) or Interferon…. 
≤ 7 days pre-tx 
▪▪ Anti-coagulation therapy (e.g., warfarin).………….. 
≤ 14 days pre-tx 
▪▪ NSAIDs, ASA, or >30,000IU/day oral vitamin E.… 
≤ 7 days pre-tx or ≤ 7 days post-tx 
Procedures in the face, scalp or neck 
▪▪ Cutaneous or RF laser treatment 
▪▪ Intense-pulsed light treatment 
▪▪ Photodynamic therapy or Photomodulation treatment 
▪▪ Botulinum toxin injection (injections of the trunk or extremities permitted) 
6 months prior to BL Visit 
▪▪ Prescription strength topical retinoids (tretinoin, adapalene, tazarotene) 
▪▪ Chemical (e.g., peels) or other cosmetic procedures within treatment area(s) 
▪▪ Excisional facial surgery (e.g., blepharoplasty, face lift, rhinoplasty) 
Investigational Drugs/Devices 
30 days prior to BL Visit 
 
All treatment/procedures received by the subject within 30 days prior to the baseline visit 
and throughout the treatment period, including the name of the procedure or drug, must 
be recorded in the electronic Case Report Form (eCRF) with end dates, if applicable. 
 
In the event such prohibited therapies are administered during the study period, subject 
participation will not automatically be discontinued. The event will be documented by the 
site staff as a protocol deviation, and depending upon the nature of the prohibited 
therapy and the timing relative to the determination of the primary endpoint, the Sponsor 
may make a decision to discontinue the subject. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 16 of 60 
(v1.0; 28-Aug-2015) 
 
 
The decision to administer a prohibited medication/treatment is done with the safety of 
the study subject as the primary consideration. If the permissibility of a specific 
medication/treatment is in question, the ethica CRO Project Manager should be 
contacted before the prohibited medication/treatment is administered. 
 
6. 
Materials 
Commercially available Bellafill and Bellafill Skin Tests will be used for the study (see 
Skin Test IFU and Bellafill IFU in Appendix 2 and 3, respectively). 
 
6.1 
Packaging and Labeling 
Open label commercially packaged supplies of Bellafill will be provided to Investigators. 
Bellafill is to be stored at standard domestic refrigerator temperature. 
 
6.2 
Treatment Regimen/Volume Allowances 
The total treatment volume used per subject is dependent on the number and size of 
scars treated; however, the maximal volume of Bellafill to be injected in a subject is 8.9 
ml per treatment session. 
 
6.3 
Supplies and Accountability 
The Investigator/pharmacist will take inventory and acknowledge receipt of all shipments 
of Bellafill. Bellafill must be kept in a locked area with access restricted to designated 
study personnel. The Investigator or designee will also keep accurate records of the 
volumes of Bellafill injected. Unused syringes will be returned to the Sponsor unless 
other disposition arrangements are agreed upon in writing with the Sponsor. 
 
6.4 
Other Study Supplies 
Supplies that are unique to this study will be provided by the Sponsor (e.g., UPTs, etc.). 
The Investigator is responsible for routine supplies related to pre and post-treatment 
care (e.g., alcohol wipes, gauze, etc.). 
 
7. 
Study Methods and Procedures 
7.1 
Informed Consent and Subject Privacy 
The purpose, procedures, risks, benefits, and alternatives to study participation will be 
discussed with each potential subject. Prior to any study-related procedures subjects 
must give their written informed consent. The subject must also give Authorization for 
Use and Release of Health and Research Study Information (HIPAA), authorization to 
take identifying clinical photographs for scientific and regulatory use and other written 
documentation required by local regulations and/or the reviewing IRB prior to any study- 
related procedures. 
 
7.2 
Procedures for Final Study Entry 
A subject is considered “Enrolled” when s/he has signed the IRB-approved informed 
consent form (ICF) and HIPAA authorization in the presence of the Investigator or 
designee. The Investigator (or designee) will collect and record medical and cosmetic 
procedure histories, and females of childbearing potential must have pregnancy test 
results evaluated as negative. All subjects must also have a negative Bellafill skin test. 
The Investigator will assure that each subject meets the washout requirements and 
eligibility criteria before randomization for study treatment. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 17 of 60 
(v1.0; 28-Aug-2015) 
 
 
7.3 
Subject Identification and Treatment Allocation 
All subjects who have signed an ICF will receive a 3-digit subject number, starting at 
001. This subject number will be used to identify the subject throughout the study. 
Subject numbers will be assigned in ascending order and will be coupled with the site 
identification number for unique identification of each subject. Subjects withdrawn from 
the study will retain their subject number; new subjects will be allotted a new subject 
number. 
 
All enrolled subjects will receive treatment with Bellafill. 
 
7.4 
Blinding 
This is an open-label study and blinding does not apply. 
 
8. 
Efficacy Assessments 
Prior to enrollment of any study subjects, the Investigators will be trained in the use of all 
efficacy assessment scales. Subjects will receive training on how to perform the self- 
assessments during the study. The following assessments will be conducted: 
 Acne Scar Assessment Scale (ASAS): a validated 5-point static scale assessing physician 
impression of acne scar severity; 
 
Physician Global Aesthetic Improvement Scale (PGAIS): a 5-point dynamic scale assessing 
cosmetic improvement; 
 
Subject Global Aesthetic Improvement Scale (SGAIS): a 5-point dynamic scale assessing 
cosmetic improvement; 
 Subject QOL Impact Scale: (33 questions): a 33-question survey that allows the subject to 
specifically address how acne scarring has affected his/her emotional and functional status. 
 
See Appendix 1 for additional details regarding the assessments used in this study. 
 
8.1 
Photography 
Facial photography will also be employed in this study. Baseline photographs will be 
used for PGAIS and SGAIS assessments. Canfield Scientific Inc. will provide each site 
with photographic equipment, training and an Instruction Manual prior to the start of the 
study. 
 
9. 
Safety Assessments 
Throughout the study, subjects will be instructed to report any unusual signs or 
symptoms to the Investigator. 
 
The Investigator will solicit and record information about AEs, and concomitant 
medications, therapies and treatments. At each post-treatment visit, phone call, or e- 
mail contact, the Investigator (or designee) will begin by asking the subject a general, 
non-directed question such as ‘How have you been feeling since the last visit?’ Directed 
questioning and examination will then be done as appropriate. All reported AEs will be 
documented in the eCRF. 
 
10. 
Schedule of Study Activities 
Subjects must have a negative Bellafill skin test prior to receiving study treatment. 
Additionally, a negative screening urine pregnancy test is required for women of 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 18 of 60 
(v1.0; 28-Aug-2015) 
 
 
childbearing potential. Please refer to the following assessment schedule for additional 
details: 
 
10.1 
Assessment Schedule 
 
Visit 
1 
2 
3 
4 
5 
1 month = 28D 
M0 
screening 
D0 
±3D 
M1 
±5D 
M4 
±7D 
M7 
±7D 
Informed Consent 
X 
Incl/Excl Criteria, Med Hx 
X 
X 
confirm 
UPT (if applicable) 
X 
X1 
X1 
Facial Scar Photography 
X 
X 
Bellafill Skin Test 
X 
Placement 
X 
Reading 
Bellafill Injections 
Initial injection 
Touch-up 
I 
T 2 
Assessments 
ASAS (Investigator) 
X 
X 
X 
PGAIS (Investigator) 
X 
X 
SGAIS (subject) 
X 
X 
QoL Scar Impact Scale (subject) 
X1 
X 
Con Meds/Procedures 
X 
X 
X 
X 
X 
Adverse Events 
X 
X 
X 
X 
X 
1 Assessments to be performed prior to Bellafill treatments 
2 Bellafill touch- up injections administered as necessary 
 
10.2 
Study Procedures 
10.2.1 Visit 1: Screening Visit (Month -1) 
The following activities will be conducted: 
▪▪ Informed Consent/HIPAA 
▪▪ Subject Demographics/Medical History and Inclusion/Exclusion Criteria 
▪▪ UPT (if applicable) 
▪▪ Concomitant Medication/Procedures 
▪▪ Bellafill skin test and record the location of placement for review at the next visit 
- 
If applicable, collect any AEs, if any observed immediately after skin testing. 
▪▪ Facial Scar Photography 
▪▪ ASAS 
- 
Performed by the Investigator. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 19 of 60 
(v1.0; 28-Aug-2015) 
 
 
10.2.2 Visit 2: Treatment Visit (D0 ± 3D) 
The following activities will be conducted: 
▪▪ Inclusion/Exclusion Criteria (confirmation) 
▪▪ UPT (if applicable) 
▪▪ Review skin test results and inclusion/exclusion criteria to confirm eligibility 
▪▪ QoL Scar Impact Scale 
- 
Performed by the subject prior to receiving Bellafill injections. 
▪▪ Bellafill injections 
▪▪ 
Document the number of scars treated as well as the method and volume of treatment. 
▪▪ Concomitant Medication/Treatment and AE assessment 
▪▪ Remind subject of prohibited treatments and appropriate post-treatment care 
 
10.2.3 Visit 3 (M1 ± 5D) 
The following activities will be conducted (conduct assessments prior to touch-up): 
▪▪ Concomitant Medication/Procedures and AE assessment 
▪▪ UPT (if applicable, and if a subject is to receive touch-up treatment) 
▪▪ Touch-up Study Treatment 
- 
The Investigator will examine the subject and determine if touch-up treatment is required to 
achieve optimal correction. Previously treated scars determined to be undercorrected  will 
receive touch-up treatment. New scars (i.e., previously untreated) may not be treated. 
- 
Document the number of scars treated as well as the method and volume of treatment. 
- 
Subjects who merit additional treatment but decline touch-up treatment will not be retreated but 
will continue to participate in the study if they otherwise consent to continued participation. 
▪▪ Remind subject of prohibited treatments and appropriate post-treatment care 
 
10.2.4 Visit 4 (M4 ± 7D) 
The following activities will be conducted: 
▪▪ Concomitant Medication/ Procedures and AE assessment 
▪▪ ASAS and PGAIS 
- 
The Investigator will refer to Baseline photographs for PGAIS evaluation. 
▪▪ SGAIS 
- 
The subject will refer to Baseline photographs for SGAIS evaluation. 
▪▪ Remind subject of prohibited treatments and appropriate post-treatment care 
 
10.2.5 Visit 5 (M7 ± 7D) 
The following activities will be conducted: 
▪▪ Concomitant Medication/ Procedures and AE assessment 
▪▪ Facial Scar Photography 
▪▪ ASAS and PGAIS 
- 
The Investigator will refer to Baseline photographs for PGAIS evaluation. 
▪▪ QoL Scar Impact Scale and SGAIS 
- 
The subject will refer to Baseline photographs for SGAIS evaluation. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 20 of 60 
(v1.0; 28-Aug-2015) 
 
 
10.3 
Instructions for Subjects 
Prior to attending all study visits, subjects must refrain from applying facial cosmetics. 
Makeup may be re-applied after the study visits at the discretion of the Investigator. 
 
Subjects should avoid strenuous exercise, consumption of alcoholic beverages and 
extended exposure to sun or heat for at least 24 hours after treatment to reduce the risk 
of post treatment redness, swelling, and/or itching. Subjects will also be advised not to 
manipulate or massage injected areas. 
 
Subjects will be instructed to contact the Investigator or his/her research staff to report 
any unexpected symptoms or to ask any questions about the study. 
 
10.4 
Unscheduled Visits 
Each time the subject returns to the study site the Investigator will solicit and record 
information about AEs, and concomitant medications, therapies and treatments. An 
interim or unscheduled visit may replace a scheduled visit if it occurs within the 
acceptable time window for a scheduled visit or if the scheduled visit was missed. All 
applicable procedures should be performed. 
 
10.5 
Early Discontinuation/Withdrawal 
It is the right and duty of the Investigator to discontinue a subject’s participation when the 
subject's health or well-being is threatened by continuation in the study. Such subjects 
should be withdrawn from the study and not continued under a modified regimen. In the 
event of premature discontinuation, the Investigator should determine the primary 
reason for discontinuation. A subject who is withdrawn from the study prior to initiation  
of treatment may be replaced. The following are circumstances that may result in the 
subject's discontinuation from the study: 
▪▪ 
the subject experiences a serious AE rendering them unable to continue study participation; or 
▪▪ 
the subject is unable to physically or mentally tolerate the test treatment; or 
▪▪ 
the subject voluntarily withdraws; or 
▪▪ 
the subject receives a prohibited therapy that could significantly confound the results. 
 
Subjects may voluntarily withdraw from the study at any time without jeopardy to future 
medical care. They may also be administratively withdrawn if they fail to return for follow- 
up. If a subject chooses to withdraw from the study, the subject will be encouraged to 
have a final assessment and undergo the final procedures listed in the protocol. 
 
For any subject who withdraws from the study the date and reason for withdrawal will be 
recorded on the eCRF. If an AE is ongoing at the time of the withdrawal, the Investigator 
will attempt to follow the subject until the AE has resolved or stabilized or until follow-up 
is no longer possible. 
 
10.6 
Lost to Follow-Up 
Significant efforts will be made to encourage all subjects to complete the study. For 
subjects that are lost to follow-up the site will contact the subject’s secondary contact if 
listed in the subject’s medical record or the subject identification log as another means to 
contact the subject. If this is unsuccessful a final certified letter will be sent by the 
Investigator notifying the subject of the need and importance to follow-up. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 21 of 60 
(v1.0; 28-Aug-2015) 
 
 
10.7 
Study Termination 
The Sponsor reserves the right to terminate this study for any reason upon reasonable 
notice to the Investigators. 
 
If conditions arise during the study that indicate that the study or an investigational site 
should be terminated, the Sponsor, Investigator, Monitor, IRB, and/or regulatory 
agencies will discuss the situation and take appropriate action after consultation. 
 
Conditions warranting termination of the study or site include, but are not limited to: 
▪▪ 
The discovery of an unexpected, serious, or unacceptable risk to subjects enrolled in the study; 
▪▪ 
The decision on the part of the Sponsor to suspend or discontinue testing, evaluation, or 
development of the study device; 
▪▪ 
Failure of the Investigator to comply with pertinent national or state regulations, IRB-imposed 
conditions, or protocol requirements; 
▪▪ 
Submission of knowingly false information from the Investigator to the Sponsor, Monitor, IRB, or 
any regulatory agency. 
 
11. 
Adverse Events 
Throughout the course of the study, all AEs will be monitored and reported through the 
AE eCRF. If an AE occurs, the first concern will be the safety of the study subjects. All 
AEs occurring after study device administration will be followed until the event has 
resolved or stabilized or until follow-up is no longer possible. 
 
11.1 
Definitions 
11.1.1 Adverse Events (AEs) 
An AE is defined as any undesirable physical, psychological or behavioral effect 
experienced by a subject during his/her participation in a study, in conjunction with the 
use of the device, whether or not it is considered procedure or product related. AEs may 
include, but are not limited to, subjective or objective symptoms spontaneously offered 
by the subject, solicited via subject interviews, uncovered by review of concomitant 
medications or therapies, and/or observed by the Investigator. The Investigator will 
record the description (sign, symptom, or diagnosis), onset, resolution, seriousness, 
severity, cause and action taken for any event on the AE eCRF. 
 
Disease signs and symptoms that existed prior to the study injections are not considered 
AEs unless the condition recurs after the subject has recovered from the pre-existing 
condition or the condition worsens in intensity or frequency during the study. 
 
Commonly-reported AEs in previous studies include the following local skin changes: 
swelling, redness, pain, bruising, lumps/bumps, itching skin discoloration, increased 
sensitivity, telangiectasias in implant area, scar, edema, abscess or infection, recurrence 
of a pre-existing herpes labialis, ulceration, erosion or necrosis, itching or burning, pain 
and/or tenderness, granuloma formation, and skin blanching. Additionally, systemic 
findings reported in prior studies include: drop in blood pressure or anaphylactic shock, 
difficulty breathing, tightness in chest, shortness of breath, immune mediated diseases, 
tingling, numbness, temporary pain in various areas of the body, flu-like symptoms, 
blurred vision, or hypersensitivity to bovine collagen. The relevance of these findings to 
the current Bellafill product is not known. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 22 of 60 
(v1.0; 28-Aug-2015) 
 
 
11.1.2 Common Treatment Responses (CTRs) 
Common Treatment Response (CTRs) following the use with a dermal filler include 
redness, pain, tenderness, firmness, swelling, lumps/bumps, bruising, itching and 
discoloration. CTRs will not be recorded as AEs unless the duration and/or severity are 
in excess of that typically observed following injection of a dermal filler, and are clinically 
significant as determined by the Treating Investigator. 
 
11.1.3 Serious Adverse Events and Unexpected Adverse Device Effects 
A Serious Adverse Event (SAE) is any AE that results in any of the following: 
▪▪ 
Death 
▪▪ Life-threatening injury or illness – any AE that places the subject, in the view of the reporter, at 
immediate risk of death from the AE as it occurred (It does not include an AE that, had it occurred   
in a more severe form, might have caused death) 
▪▪ Inpatient hospitalization or prolongation of existing hospitalization. However, preplanned or elective 
hospitalizations for pre-existing conditions that have not worsened during the course of the study 
should not be considered SAEs 
▪▪ Persistent or significant disability/incapacity – any AE that results in a substantial disruption of the 
subject’s ability to conduct normal life functions 
▪▪ Important medical events that may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed above 
An Unexpected Adverse Device Effect (UADE) is any device-related AE that meets one 
or more of the following criteria: 
▪▪ 
Is not identified in nature, severity or frequency in current literature on the product 
▪▪ 
Is life threatening, even if temporary in nature 
▪▪ 
Results in permanent impairment of a body function or permanent damage to a body structure 
▪▪ 
Necessitates medical or surgical intervention to preclude permanent impairment of a body function or 
permanent damage to a body structure 
 
Also considered an UADE is any device malfunction that would be likely to cause or 
contribute to a death or serious injury if the malfunction were to recur. 
 
11.1.4 Severity 
Definitions for classification of severity appear below. For events reported on the AE 
eCRF, the Investigator will determine the severity classification based on these 
definitions, his/her clinical experience in the use of dermal fillers, and/or the subject’s 
description of the event. [Note: A “severe” AE is not the same as a “serious adverse 
event,” which is defined above.] 
▪▪ Mild: Symptoms are barely noticeable or do not make the subject uncomfortable. The AE does not 
influence performance or functioning. Prescription drugs are not ordinarily needed for relief of 
symptom(s). 
▪▪ 
Moderate: Symptoms are of sufficient severity to make the subject uncomfortable. Performance of   
daily activities is influenced. Tx of symptom(s) with prescription drugs or therapies may be needed. 
▪▪ 
Severe: Symptoms are of sufficient severity to cause the subject severe discomfort. Performance of 
daily activities is compromised. Tx for symptom(s) with prescription drugs or therapies may be needed. 
 
11.1.5 Relationship to Study Device 
The Investigator will determine relatedness of the subject’s symptom or problem to the 
study device or the injection procedure. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 23 of 60 
(v1.0; 28-Aug-2015) 
 
 
11.2 
Procedures for Reporting Adverse Events 
All AEs should be recorded through the AE eCRF. 
 
11.3 
Procedures for Unmasking of Study Devices 
Not applicable. This is an open-label study. 
 
11.4 
Pregnancy 
A female is considered a Woman of Childbearing Potential (WOCBP) unless she is 
postmenopausal for at least 12 months prior to study treatment administration, without a 
uterus and/or both ovaries, or has been surgically sterile for at least 6 months prior to 
study treatment administration. 
 
In order to participate in the study, sexually active WOCBP must use one of the following 
reliable methods of contraception: hormonal methods or intrauterine device in use ≥90 
days prior to study treatment administration, barrier methods plus spermicide in use ≥14 
days prior to study treatment administration, or vasectomized partner. Non-sexually 
active WOCBP will not be required to practice a reliable method of contraception. These 
subjects may be enrolled at the Investigator’s discretion if they are counseled to remain 
sexually inactive during the study and understand the possible risks in getting pregnant 
during the study. 
 
12. 
Statistics 
12.1 
Sample Size Justification 
Approximately 50 subjects will be enrolled. This is a pilot study and a formal sample  
size justification is not provided for this study. It is the opinion of the Sponsor that a total 
of 50 subjects will be sufficient to achieve the objectives of the study. 
 
12.2 
Efficacy Parameter Analysis 
Statistical analyses will be conducted on an intent-to-treat (ITT) basis (i.e., all enrolled 
subjects that have fully passed screening and have received initial treatment with Bellafill 
will be included in the analyses). Descriptive statistics (i.e., mean, standard deviation, 
etc.) will be provided for all continuous variables and frequencies for all categorical 
variables collected in this study. When appropriate, exploratory inferential statistical 
analyses will be conducted using SAS® software (9.3 or higher). Comparisons and 
correlations of interest will be performed using parametric or non-parametric testing, as 
appropriate. The level of significance will be fixed at 0.05. No adjustments for multiplicity 
will be performed. 
 
Summary tables will be used to present population characteristics at Baseline. Data  
from the study questionnaires will be included. For categorical parameters, the number 
and percentage of subjects in each category will be presented. The denominator for 
percentage will be based on the number of subjects appropriate for the purpose of 
analysis. For continuous parameters, descriptive statistics will include n (number of 
subjects), mean, standard deviation, median, and range. No imputation will be used to 
account for missing data. No particular processing for outliers will be performed. Data 
will be presented as reported in the eCRF. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 24 of 60 
(v1.0; 28-Aug-2015) 
 
 
Subgroup analyses will consist of gender, age, and Fitzpatrick skin type. Analyses  
within each subgroup may be limited to specific outcomes of interest and will be defined 
in the statistical analysis plan. 
 
12.3 
Safety Analysis 
Safety analyses will be performed in terms of incidence and severity of adverse events. 
These will be tabulated and a complete listing of all reports of adverse and/or 
unexpected events will be presented. 
 
Concomitant medications will be coded to generic terms. The listing will include study 
treatment date, start and stop date, and whether the drug was taken during study 
treatment. 
 
13. 
Administrative Issues 
This protocol will be conducted in accordance with the applicable U.S. Food and Drug 
Administration (FDA) regulations and guidelines and ICH-GCP Guidelines. 
 
13.1 
Protection of Human Subjects 
13.1.1 Compliance with Informed Consent Regulations (21 CFR Part 50) 
Written informed consent will be obtained from each subject prior to enrollment into the 
study (i.e., before performing any screening evaluations or procedures). 
 
13.1.2 Compliance with Institutional Review Board Regulations (21 CFR Part 56) 
This study will be conducted in accordance with IRB regulations (U.S. 21 CFR Part 
56.103). The Investigator must obtain approval from a properly constituted IRB prior to 
initiating the study and obtain re-approval at least annually. 
 
13.1.3 Compliance with the ICH-GCP Guidelines (ICH E6) 
This protocol will be conducted in accordance with the applicable ICH-GCP Guidelines 
(ICH E6). 
 
13.2 
Changes to the Protocol 
Strict adherence to the protocol is necessary to assure validity of the study. The 
Investigator must notify the Sponsor or designee and the reviewing IRB of significant 
deviations from this protocol. Significant deviations to the protocol will be documented 
and maintained as part of the study record. Lost to follow-up, out of window visits or 
assessments missed due to the subject’s non-participation will be documented, but not 
considered significant deviations. 
 
The Investigator must not implement any changes to the protocol without approval by 
the Sponsor and prior review and documented approval from the IRB, except where 
necessary to eliminate immediate hazards to study subjects, or when the changes 
involve only logistical or administrative aspects of the study (e.g., change of telephone 
numbers). 
 
No amendments to the protocol will be implemented without the prior written consent of 
the Sponsor. Should an amendment be necessary, the reviewing IRB and FDA may 
require review and approval of it prior to implementation. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 25 of 60 
(v1.0; 28-Aug-2015) 
 
 
13.3 
Subject Confidentiality and Privacy 
A report of the results of this study may be published or sent to the appropriate health 
authorities in any country in which the study device may ultimately be marketed, but the 
subject’s name will not be disclosed in these documents. The subject's name may be 
disclosed to the Sponsor of the study (Suneva), the CRO (ethica CRO Inc.), the 
governing health authorities (e.g., FDA) if they inspect the study records. Appropriate 
precautions will be taken to maintain confidentiality of medical records and personal 
information. 
 
Written authorization will be obtained from each subject prior to enrollment into the study 
in accordance with the applicable privacy requirements (e.g., the Health Insurance 
Portability and Accountability Act Standards for Privacy of Individually Identifiable Health 
Information - HIPAA). 
 
13.4 
Required Regulatory Documents 
It is the responsibility of the Investigator and study staff to maintain a comprehensive 
and centralized filing system of all study-related documentation, which is suitable for 
inspection at any time by the study monitor, the IRB, and the FDA. Elements should 
include: 
• 
Subject files containing the completed case report forms, supporting source documentation and the 
informed consent, with signatures by the Investigator or sub-Investigators. 
• 
Pharmacy or Investigator files, containing the investigational agent accountability records or 
dispensation logs and all study agent related correspondence. 
• 
Confidential disclosure agreement with the Sponsor. 
• 
Financial disclosure forms for each Investigator or sub-Investigator. 
• 
Study files, containing the following required documentation: 
- 
Protocol with all amendments 
- 
The Skin Test IFU (Appendix 2) and Bellafill IFU (Appendix 3) 
- 
Copies of all pre-study documentation and all correspondence to and from the IRB and the 
Sponsor or Sponsor representatives 
- 
An up-to-date curriculum vitae for the principal Investigator. 
- 
Signed and dated Investigator agreement 
- 
Copies of all written communications with the IRB including all approval forms. 
- 
A copy of the IRB approved informed consent form and other adjunctive materials (e.g., 
advertising) used in the study, including written documentation of IRB approval of these items. 
- 
In addition to the documents required prior to the study, other documentation may be required 
during the course of the study. 
 
13.4.1 Source Documents 
Individual subject records will be maintained in the Investigator’s Source Documents 
(SDs). Source documentation is generally considered to be the document on which the 
information or data point was first recorded. SDs may include a source document 
worksheets, subject's medical records, hospital charts, clinic charts, and the 
Investigator's study files as well as the results of diagnostic tests such as X-rays, 
laboratory tests, and electrocardiograms. 
 
13.4.2 Electronic Case Report Form (eCRF) Completion 
Treatment and follow-up of subjects will be recorded in a 21 CFR part 11 compliant 
eCRF. Data will be first recorded into the medical record and study specific source 
document worksheets, as applicable, prior to entry into the eCRF. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 26 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
The study coordinator will refer to the source document worksheets in conjunction with 
the medical record in order to complete data entry into the eCRF. 
 
In order to review and electronically sign the eCRF, the Investigator will have individual 
login passwords that will allow them to entered data. The Investigator must ensure that 
they electronically sign for completed eCRFs on a timely basis. 
 
13.4.3 Study Summary 
The Investigator will submit to the Sponsor on a regular basis copies of the Study Visit 
Log, which lists all enrolled subjects by Subject Number, initials, and dates of completed 
visits. The Investigator will submit a final progress report to his/her reviewing IRB within 
3 months of study completion at the site. The Investigator will also provide additional 
reports to the IRB or to the Sponsor upon request. 
 
13.4.4 Retention of Documentation 
Essential documents are any records that demonstrate the compliance of the subject, 
Investigator, Sponsor, and Monitor with the study protocol, ICH-GCP Guidelines, and 
with all applicable regulatory requirements. Essential documents (including but not 
limited to study-related correspondence, subject records, subject privacy documentation, 
records of the distribution and use of all investigational devices, source document 
worksheets, and hardcopies of eCRFs) should be retained and available for audit by the 
Sponsor’s auditor and regulatory authorities until at least 2 years after completion or 
termination of the study. Suneva requires that it be notified in writing if the Investigator 
chooses to store the records at a different physical address than the site address or if 
the Investigator wishes to relinquish ownership of the data so that mutually agreed-upon 
arrangements can be made for transfer of ownership to a suitably qualified, responsible 
person. 
 
13.5 
Monitoring by the Sponsor 
Clinical research staff (monitors) designated by the Sponsor may visit the study center 
periodically to monitor adherence to the protocol and to applicable FDA regulations, and 
the maintenance of adequate and accurate clinical records. Monitoring functions will be 
performed in compliance with ICH-GCP Guidelines. The Investigator agrees to allow 
these personnel access to the clinical supplies, the Bellafill dispensing and storage area, 
subject medical records, laboratory data, and other source documentation of the study 
subjects. 
 
13.6 
On-Site Audits 
The FDA, in the form of a trained and properly-authorized employee of the department, 
may request access to all study records, including source documents, for inspection and 
copying, in keeping with FDA regulations. The Investigator should immediately notify the 
Sponsor of an upcoming inspection. An auditing inspection may also be conducted by a 
representative of the Sponsor’s Quality Assurance department. 
 
13.7 
Proprietary Information 
The information generated during this study is considered to be the property of the 
Sponsor and cannot be used in publication without the written consent of the Sponsor. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 27 of 60 
(v1.0; 28-Aug-2015) 
 
 
13.8 
Publications 
Suneva, as the Sponsor, has a proprietary interest in this study. Authorship and 
manuscript composition will reflect joint cooperation among multiple Investigators and 
sites and Sponsor personnel. Authorship will be established prior to the writing of the 
manuscript. As this study involves multiple centers, no individual publications will be 
allowed prior to completion of the final report of the multi-center study except as agreed 
with the Sponsor. 
 
13.9 
References 
1. 
Goodman, Greg J. “Postacne Scarring: A Review of its Pathophysiology and Treatment.” Dermotol 
Surgery, American Society for Dermatologic Surgery Inc., Blackwell Publishing, 2000. 
2. 
Goodman, Greg J, & Baron, Jennifer A. “Postacne Scarring: A Qualitative Global Scarring Grading 
System.” Dermatol Surgery, ASDS, Blackwell Publishing, 2006. 
3. 
Berson, Diane S. “Millions of Women Facing Adult Acne.” Presented at ACADEY ’04, New York, July 
30 2004. Retrieved September 2007 from the American Academy of Dermatology Public Resource 
Center from www.aad.org/public/news/newrelease. 
4. 
Holland, D.B., Jeremy, A.H.T., Roberts, S. G., Seukeran, D.C., Layton, A.M., & Cunliffe, W. J. 
“Inflammation in Acne Scarring: A Comparison of the Responses in Lesions from Patients Prone and 
Not Prone to Scar.” British Journal of Dermatology, British Association of Dermatologists, 2004. 
5. 
Jacob, C.I., Dover, J.S., & Kaminer, M.S. “Acne Scarring: A Classification System and Review of 
Treatment Options.” Journal of the Academy of Dermatology, American Academy of Dermatology, Inc., 
July 2001. 
6. 
Munavalli, G., Smith, S., McDaniel, D. Personal communication of experiences, September 2007. 
7. 
Lee, J.B., Chung, W.G., Kwahck, H., & Lee, K.H. “Focal Treatment of Acne Scars with Trichloroacetic 
Acid: Chemical Reconstruction of Skin Scars Method.” Dermatol Surgery, ASDS, Blackwell Publishing, 
Nov 2002. 
8. 
“Acne Treatment Revolutionized by 25 Years of Research.” Retrieved September 2007 from Acne Net, 
online resource of American Academy of Dermatology, from www.skincarephysicians.com/acnenet. 
9. Leheta, T., El Tawdy A., Abdel Hay R., Farid, S. Percutaneous collagen induction versus full- 
concentration trichloroacetic acid in the treatment of atrophic acne scars. Dermatol Surg 2011; 37 (2): 
207-16 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 28 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
APPENDICES 
 
Appendix 1: 
Study Assessments 
Appendix 2: 
Skin Test Instructions for Use 
Appendix 3: 
Bellafill Instructions for Use 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 29 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
APPENDIX 1: Study Assessments 
 
A. Acne Scar Assessment Scale (ASAS): The ASAS is a static assessment scale that 
allows the Investigator to measure his/her impression of acne scare severity within the 
treatment area. The four (4) Individual segments of the treatment area will be assessed 
separately, then will be averaged to obtain a global score. 
 
Term 
Grade 
Description 
Clear 
1 
No depressions are seen in the treatment area. Macular discoloration may be seen. 
Very Mild 
2 
A single depression is easily noticeable with direct lighting (deep). Most or all of the 
depressions seen are only readily apparent with tangential lighting (shallow). 
Mild 
3 
A few to several, but less than half of all the depressions are easily noticeable with 
direct lighting (deep). Most of the depressions seen are only readily apparent with 
tangential lighting (shallow). 
Moderate 
4 
More than half of the depressions are apparent with direct lighting (deep). 
Severe 
5 
All or almost all the lesions can be seen with direct lighting (deep). 
 
 
 
B. Physician Global Aesthetic Improvement Scale (PGAIS): The Investigator will 
refer to baseline photographs and assess global overall improvement (but without 
considering untreated scars) as per the following: 
 
5 = Much improved 
Marked improvement in appearance from the initial condition, touch-up 
treatment(s) is not indicted 
4 = Improved 
Obvious improvement in appearance from the initial condition, but a touch-up 
or re-treatment is indicated 
3 = No change 
The appearance is essentially the same as the original condition 
2 = Worse 
The appearance is worse than the original condition 
1 = Much Worse 
The appearance is much worse than the original condition 
 
 
 
C. Subject Global Aesthetic Improvement Scale (SGAIS): The degree of aesthetic 
improvement will be assessed by the subject using the SGAIS as defined below. The 
subject will refer to baseline photographs and assess global overall improvement (but 
without considering untreated scars) as per the following: 
 
5 = Much improved 
Marked improvement in appearance from the initial condition 
4 = Improved 
Obvious improvement in appearance from the initial condition 
3 = No change 
The appearance is essentially the same as the original condition 
2 = Worse 
The appearance is worse than the original condition 
1 = Much Worse 
The appearance is much worse than the original condition 
Rating 
Description 
Rating 
Description 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 30 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
 
 
 
 
D. Quality of Life Scar Impact Scale: The following Quality of Life Scar Impact 
Scale questionnaire allows the subject to specifically address how acne scarring 
has affected his/her emotional and functional status: 
 
Please circle the number that best describes how you feel. Circling the number one suggests that 
you believe that the description on the left hand column best describes how you feel. Circling the 
number 7 suggests that you believe that the description on the right hand column best describes 
how you feel. Circling number 4 suggests that you feel neutral or that there has been no change. 
Please be honest. 
 
The amount and appearance of my acne scarring causes me to feel . . . 
 
1. Less anxious    1   2   3   4   5   6   7 
More anxious 
2. More optimistic    1   2   3   4   5   6   7 
Less Optimistic 
3. More energetic    1   2   3   4   5   6   7 
Less energetic 
4. Eating more healthy food 
1   2   3   4   5   6   7 
Eating less healthy food 
5. Happier   1   2   3   4   5   6   7 
Sadder 
6. Exercising more    1   2   3   4   5   6   7 
Exercising less 
7. Less irritable    1   2   3   4   5   6   7 
More irritable 
8. More amorous 1 
2 3 4 5 6 7 
Less amorous 
9. More social 1 2 
3 4 5 6 7 
Less social 
10. More productive 
1 2 3 4 5 6 7 
Less productive 
11.  More focused 
1 2 3 4 5 6 7 
Less focused 
12. Less tired 
1   2   3   4   5   6   7 
More tired 
13. Less angry 
1   2   3   4   5   6   7 
More angry 
14. More confident 
1   2   3   4   5   6   7 
Less confident 
15. More sexually confident 
1   2   3   4   5   6   7 
Less sexually confident 
16. More assertive 
1   2   3   4   5   6   7 
Less assertive 
17. Less argumentative 
1   2   3   4   5   6   7 
More argumentative 
18. More comfortable with others 
1   2   3   4   5   6   7 
Less comfortable with others 
19. More likely to go out    1   2   3   4   5   6   7 
Less likely to go out 
20. More involved in community activities  1   2   3   4   5   6   7 
Less involved in community activities 
21. Doing better at work/school    1   2   3   4   5   6   7 
Doing worse at work/school 
22. More in control 
1   2   3   4   5   6   7 
Less in control 
23. Taking more medications 
1   2   3   4   5   6   7 
Taking less medications 
24. Less depressed    1   2   3   4   5   6   7 
More depressed 
25. Seen by others as less stressed 1 2 3 4 5 6 7 Seen by others as more stressed 
26. Feeling more attractive    1   2   3   4   5   6   7 
Feeling less attractive 
27. More relaxed 
1   2   3   4   5   6   7 
Less relaxed 
28. Happier when looking in mirror 1 2 3 4 5 6 7 Less happy looking in mirror 
29. Using less cosmetics to hide scars 1 2 3 4 5 6 7 Using more cosmetic to hide scars 
30. Happier when my face is touched 1 2 3 4 5 6 7 Less happy when my face is touched 
31. My life is better 
1   2   3   4   5   6   7 
My life is worse 
32. Drinking more alcohol 
1   2   3   4   5   6   7 
Drinking less alcohol 
33. Happier with my body    1   2   3   4   5   6   7 
Less happy with my body 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 31 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
APPENDIX 3: Skin Test Instructions for Use 
 
 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 32 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
 
 
 
 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 33 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
 
 
 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 34 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 35 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 36 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
 
 
 
 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 37 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
APPENDIX 3: Bellafill Instructions for Use 
Bellafill® 
Instructions for Use 
Caution: Federal Law restricts this device to sale by or on the order of a physician or 
licensed practitioner. 
DESCRIPTION 
Bellafill1 is an implant composed of non-resorbable polymethylmethacrylate (PMMA) 
microspheres, 30 to 50 microns in diameter, suspended in a water-based carrier gel 
composed of 3.5% bovine collagen, 92.6% buffered, isotonic water for injection, 0.3% 
lidocaine hydrochloride, 2.7% phosphate buffer, and 0.9% sodium chloride. 
 
INTENDED USE / INDICATIONS 
Bellafill is indicated for the correction of nasolabial folds and moderate to severe, 
atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. 
 
CONTRAINDICATIONS 
• Bellafill is contraindicated for patients displaying a positive response to the 
required Bellafill Skin Test. Refer to the Bellafill Skin Test Instructions for 
Use for complete instructions for administration and evaluation of the Skin 
Test. 
• Bellafill is contraindicated for patients with severe allergies manifested by a 
history of anaphylaxis or history or presence of multiple severe allergies. 
• Bellafill contains lidocaine and is contraindicated for patients with known 
lidocaine hypersensitivity. 
• Bellafill contains bovine collagen and is contraindicated for patients with a history 
of allergies to any bovine collagen products, including but not limited to injectable 
collagen, collagen implants, hemostatic sponges, and collagen-based sutures, 
because these patients are likely to have hypersensitivity to the bovine collagen in 
Bellafill. 
• Bellafill is contraindicated for patients undergoing or planning to undergo 
desensitization injections to meat products, as these injections can contain bovine 
collagen. 
• Bellafill is contraindicated for patients with bleeding disorders. 
 
• Bellafill is contraindicated for use in lip augmentation and injection into the 
vermilion or the wet mucosa of the lip. 
• Bellafill should not be used in patients with known susceptibility to keloid 
formation or hypertrophic scarring. 
 
1 Bellafill® formerly known as ArteFill® 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 38 of 60 
(v1.0; 28-Aug-2015) 
 
 
WARNINGS 
• The safety of Bellafill when used within 6 months of collagen, botulinum toxin, 
or other wrinkle therapies has not been studied. 
• A Bellafill Skin Test must be administered and evaluated prior to injection of 
Bellafill. Patients demonstrating a positive Skin Test or 2 equivocal Skin Tests 
should not be considered candidates for treatment. Patients demonstrating an anti- 
bovine collagen serum IgG level outside of the normal range at baseline also 
should not be considered candidates for treatment. Refer to the Bellafill Skin Test 
Instructions for Use. 
• Use of Bellafill at specific sites in which an active inflammatory process (skin 
eruptions such as cysts, pimples rashes, or hives) or infection is present should 
be deferred until the inflammatory process has been controlled. 
• Introduction of product into the vasculature may lead to embolization, occlusion 
of the vessels, ischemia, or infarction. Take extra care when injecting soft tissue 
fillers, for example inject the product slowly and apply the least amount of 
pressure necessary. Rare but serious adverse events associated with the 
intravascular injection of soft tissue fillers in the face have been reported and 
include temporary or permanent vision impairment, blindness, cerebral ischemia 
or cerebral hemorrhage, leading to stroke, skin necrosis, and damage to underlying 
facial structures. Immediately stop the injection if a patient exhibits any of the 
following symptoms, including changes in vision, signs of a stroke, blanching of 
the skin, or unusual pain during or shortly after the procedure. Patients should 
receive prompt medical attention and possibly evaluation by an appropriate health 
care practitioner specialist should an intravascular injection occur. 
 
PRECAUTIONS 
• Bellafill contains non-absorbable PMMA microspheres. Implantation is permanent 
and will not be reversed without physical removal. 
• The safety of Bellafill for use during pregnancy and in breastfeeding females has 
not been established. 
• Bellafill is packaged in a sealed tray containing individual treatment syringes with 
sterile needles for single patient use, packaged in a box. The tip of the syringe is 
sealed with a tamper-evident cover. Do not use if the seal on the tray lid or syringe 
is broken or removed. Do Not Resterilize. 
• The safety of injecting greater amounts than 3.5 cc per treatment site or 8.9 cc 
overall has not been established. 
• The safety and effectiveness of Bellafill for the treatment of non-distensible 
atrophic acne scars has not been established. The use of Bellafill for ice pick or 
sinus tract scars has not been studied. 
• The safety and effectiveness of Bellafill for nasolabial fold wrinkles and cheek 
acne scars have not been established in patients under the age of 21 years. There is 
limited information on the safety of Bellafill in patients less than 36 years of age. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 39 of 60 
(v1.0; 28-Aug-2015) 
 
 
In the pivotal Acne Scar Study of Bellafill, the incidence of injection site reactions 
in subjects less than 36 years old (30 subjects) was similar to the incidence in 
subjects above the age of 36 (113 subjects). The majority of these injection site 
reactions were mild in severity. 
• The safety in patients with known susceptibility to hyperpigmentation, keloid 
formation and hypertrophic scarring has not been studied. Formation of 
hyperpigmentation, keloids or hypertrophic scars may occur after dermal filler 
injections including Bellafill. In the pivotal Acne Scar Study of Bellafill, the 
incidence and severity of adverse events in 34 subjects with Fitzpatrick Skin Types 
V and VI was similar to that reported in 109 patients with Fitzpatrick Skin types I- 
IV and no unique adverse events associated with these patient subgroups were 
observed. 
• As with all transcutaneous procedures, Bellafill injection carries a risk of 
infection. The usual precautions associated with injectable materials should be 
followed. 
• The safety of Bellafill in patients on immunosuppressive therapy has not been 
established. 
• The safety of Bellafill in patients with connective tissue disorder has not been 
established. 
• Bruising or bleeding may occur at Bellafill injection sites. Use of Bellafill in 
patients who have undergone therapy with thrombolytics, anticoagulants, or 
inhibitors of platelet aggregation within 3 weeks preceding treatment has not 
been studied. 
• Patients should minimize exposure of the treated area to excessive sun, UV-lamp 
exposure and extreme cold weather at least until any initial swelling and redness 
has resolved. 
• If laser treatment, chemical peeling or any other procedure based on active dermal 
response is considered after treatment with Bellafill, there is a possible risk of 
eliciting an inflammatory reaction at the implant site. This also applies if Bellafill 
is administered before the skin has healed completely after such a procedure. 
• The use of Bellafill in anatomical spaces other than the dermis for correction of 
nasolabial folds and for acne scars on the cheek has not been studied. Refer to the 
Clinical Studies section for more information on implantation sites that have been 
studied. 
• The use of Bellafill in patients with thin or flaccid skin has not been 
studied and the cosmetic results for these patients are unknown. 
• Long-term safety and effectiveness of Bellafill beyond five years has not been 
established. 
• In order to minimize the risks of potential complications, this product should 
only be used by health care practitioners who have appropriate training, 
experience, and who are knowledgeable about the anatomy at and around the site 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 40 of 60 
(v1.0; 28-Aug-2015) 
 
 
of injection. 
• Health care practitioners are encouraged to discuss all potential risks of soft tissue 
injection with their patients prior to treatment and ensure that patients are aware of 
signs and symptoms of potential complications. 
• After use, treatment syringes and needles may be potential biohazards. Handle 
accordingly and dispose of in accordance with accepted medical practice and 
applicable local, state, and federal requirements. 
• Bellafill has an opaque, off-white appearance. In the event that the content of a 
syringe shows signs of separation and/or appears clear (like water), do not use the 
syringe and notify Suneva Medical immediately. In the United States or Canada, 
call toll-free 844-235- 5234. Outside of the United States or Canada call ++1-858- 
550-9999. 
• Bellafill should not be mixed with other products before implantation of the 
device. 
 
ADVERSE EVENTS 
Nasolabial Fold and Acne Scar Indications: 
A total of 1,542 patients have been treated with Bellafill in four U.S. clinical studies. 
Three of the four studies were conducted on 1,399 patients treated with Bellafill in 
support of the indication for the correction of Nasolabial Folds. One of the four studies 
was conducted on 143 patients treated with Bellafill in support of the indication for the 
correction of moderate to severe, atrophic, distensible facial acne scars on the cheek in 
patients over the age of 21 years. 
 
a) 
U.S. Controlled Nasolabial Fold (NLF) Clinical Trials 
All adverse events (AEs), including those attributed and not attributed to treatment, 
reported in Bellafill or Control subjects at an incidence of 1% or greater in U.S. studies 
are presented in Table 1 below in descending order according to frequency in the 
Bellafill group. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 41 of 60 
(v1.0; 28-Aug-2015) 
 
 
Table 1: Adverse Events Reported at an Incidence of 1% or Greater in 
U.S. Nasolabial Fold Clinical Trials of Bellafill 
Event 
Number of Events (Events/subjects 
treated, %) 
Bellafill1 
n=285 
Bellafill2 
n=106 
Control3, 4 
n=123 
Lumpiness at injection area 
more than one month after 
13 (4.6) 
4 (3.3) 
Persistent swelling or redness 
10 (3.5) 
3 (2.8) 
13 (10.6) 
Increased sensitivity 
5 (1.8) 
2 (1.9) 
Rash, itching more than 48 
hours after injection 
4 (1.4) 
2 (1.6) 
Sensitization reactions 
6 (4.9) 
Abscess 
3 (2.4) 
Visibility of puncture area 
2 (1.6) 
 
1128 Bellafill subjects in the controlled study and 157 subjects in an open label study, who were followed 
for 1 year after implantation. 
2106 Control subjects who received Bellafill in the crossover arm of the controlled study and were 
followed for 6 months after implantation. 
3123 subjects who received the Control treatment in the controlled study and were followed for 6 months 
after implantation. 
4 The Control treatment in the study was a commercially available collagen implant (Zyplast®). 
 
No systemic adverse events were reported at an incidence of 1% or greater. One severe 
adverse event (granuloma or enlargement of the implant) and 14 moderate adverse 
events (persistent swelling or redness, lumpiness at injection site more than 1 month 
after injection, blurred vision, flu-like symptoms, abscess, granuloma or enlargement of 
the implant, alopecia areata) were reported for Bellafill subjects. Nine severe adverse 
events (lumpiness at injection site more than 1 month after injection, abscess, infection, 
granuloma or enlargement of the implant, sensitization reactions, increased sensitivity, 
persistent swelling or redness), and 12 moderate adverse events (persistent swelling or 
redness, rash, itching more than 48 hours after injection, sensitization reactions, 
lumpiness at injection site more than 1 month after injection, visibility of the puncture 
area, abscess) were reported for Control subjects. 
Local adverse events reported in Bellafill subjects at an incidence of less than 1% in 
U.S. studies, whether or not they were determined to be related to the implant, were 
sensitization reactions, abscess, visibility of the puncture area, blurred vision, flu-like 
symptoms, recurrence of existing herpes labialis, granuloma or enlargement of the 
implant, acneiform lesions, occasional tenderness, redness and visible capillaries, 
alopecia areata, and dry skin. Systemic adverse events reported at an incidence of less 
than 1% were mild chest congestion and fainting. One subject was diagnosed with 
breast cancer, determined by the investigator not to be related to the implant. 
 
For Control subjects, local adverse events reported at an incidence of less than 1%, 
whether or not they were determined to be related to the implant, were increased 
sensitivity, flu-like symptoms, granuloma or enlargement of the implant, infection, and 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 42 of 60 
(v1.0; 28-Aug-2015) 
 
 
acneiform reaction. One subject died of trauma unrelated to the implant. 
 
Adverse Events Lasting Longer Than Two Weeks 
The following is a summary of the reported duration of adverse events lasting longer 
than 2 weeks in Bellafill subjects (n=391 subjects) in U.S. studies: lumpiness at 
injection site more than 1 month after injection (n=12 events), duration varied from 4 
weeks to unresolved at 26 weeks; persistent swelling or redness (n=8 events), duration 
varied from 5 weeks to unresolved at 26 weeks; increased sensitivity (n=7 events), 
duration varied from 4 weeks to unresolved at 26 weeks; rash and itching (n=2 events), 
duration varied from 3 weeks to 6 weeks; sensitization reactions (n=2 events), duration 
varied from 19 weeks to unresolved at 26 weeks; visibility of the puncture site (n=1 
event), duration was 13 weeks; granuloma or enlargement of the implant (n=4 events), 
duration varied from 10 weeks to unresolved at 26 weeks; other local complications 
(n=5 events), duration was unresolved at 26 weeks. One subject suffered from breast 
cancer unrelated to the implant. 
 
Reported duration of adverse events lasting longer than 2 weeks in Control subjects 
(n=123 subjects): lumpiness at injection site more than 1 month after injection (n=2 
events), duration varied from 13 weeks to unresolved at 26 weeks; persistent swelling or 
redness (n=12 events), duration varied from 7 weeks to unresolved at 26 weeks; 
increased sensitivity (n=1 event), duration was unresolved at 26 weeks; rash and itching 
(n=2 events), duration was unresolved at 26 weeks; sensitization reactions (n=4 events), 
duration varied from 7 weeks to unresolved at 26 weeks; abscess (n=2 events), durations 
were unresolved at 26 weeks; visibility of the puncture site (n=1 event), duration was 
unresolved at 26 weeks; granuloma or enlargement of the implant (n=1 event), duration 
was unresolved at 26 weeks; flu-like symptoms (n=1 event), duration was unresolved at 
26 weeks. One subject died from an accident unrelated to the implant. 
 
Adverse Events Reported Three Months or Longer After Treatment 
Among the 391 subjects treated with Bellafill, adverse events with reported onset dates 
3 months or more after treatment were lumpiness at the injection site (6), rash and 
itching (3), sensitization reaction (2), increased sensitivity (2), persistent swelling and 
redness (1), granuloma or granulomatous inflammation (1), alopecia areata (1), 
visibility of the puncture site (1), and redness and visible capillaries near the area of 
injection (1). 
 
Among the 123 Control subjects, adverse events with reported onset dates 3 months or 
more after treatment were abscess (1), infection (1), lumpiness (1), acneiform reaction 
(1), flu-like symptoms (1), persistent swelling or redness (1), and trauma fatality not 
related to the implant (1). 
 
b) U.S. Controlled Acne Scar Clinical Trial 
The U.S. Acne Scar pivotal study (Study SUN-11-001) involved 147 treated subjects at 
10 centers. At baseline, subjects were randomized to receive Bellafill in the cheeks or 
saline (Control group). At 6 months, all Control subjects were eligible to receive 
treatment with Bellafill. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 43 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
Of the 147 subjects treated in the study, 143 subjects received a treatment with Bellafill 
at either baseline/Day 0 (Period I) or at Month 6 (Period II, Track B). Therefore the 
safety information reflects the combination of patient outcomes for the initial (n=97) 
and crossover (n=46) Bellafill subjects (i.e., 97 + 46 = 143 total) compared to the 50 
subjects who were initially enrolled in the Control treatment arm. 
1. Subject Diary: 
Subjects were asked to keep diary cards and grade symptoms of erythema, swelling, 
bruising, pain, itching, lumps/bumps and discoloration. Subjects’ scores for the severity of 
these events after initial treatment are presented in Table 2 and durations are provided in 
Table 3,respectively. 
Subjects who observed any signs or symptoms (89.2%), experienced them shortly after 
Bellafill treatment and the majority were mild to moderate in intensity. Subjects 
typically reported these diary card symptoms as resolved in 1-7 days. Similar subject 
diary outcomes were notedfollowing touch-up treatment injections. 
 
Table 2: Maximum Intensity of Signs/Symptoms After Initial Bellafill Treatment 
From Subject Diary (n=130)* 
Sign/Symptom (R&L 
side combined) 
None n 
(%) 
Mild n 
(%) 
Moderate n 
(%) 
Severe n 
(%) 
Any sign/symptom 
14 (10.8%) 
54 (41.5%) 
51 (39.2%) 
11 (8.5%) 
Swelling 
40 (30.8%) 
48 (36.9%) 
38 (29.2%) 
4 (3.1%) 
Erythema 
44 (33.8%) 
60 (46.2%) 
23 (17.7%) 
3 (2.3%) 
Pain 
47 (36.2%) 
52 (40.0%) 
28 (21.5%) 
3 (2.3%) 
Bruising 
53 (40.8%) 
49 (37.7%) 
23 (17.7%) 
5 (3.8%) 
Lumps/bumps 
55 (42.3%) 
45 (34.6%) 
27 (20.8%) 
3 (2.3%) 
Itching 
97 (74.6%) 
26 (20.0%) 
7 (5.4%) 
0 (0.0%) 
Discoloration 
102 (78.5%) 
21 (16.2%) 
6 (4.6%) 
1 (0.8%) 
* Number of treated subjects returning diaries, combined for Period I and Period II data 
Percentages are based on the number of subjects returning diaries 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 44 of 60 
(v1.0; 28-Aug-2015) 
 
 
Table 3: Duration of Signs/Symptoms after Initial Bellafill Treatment From 
Subject Diary (n=130)* 
Sign/Symptom (R&L 
side combined) 
Any 
1day 
2–7days 
8–14days 
Any sign/symptom 
116 (89.2%) 
7 (5.4%) 
61 (46.9%) 
48 (36.9%) 
Erythema 
86 (66.2%) 
34 (26.2%) 
39 (30.0%) 
13 (10.0%) 
Swelling 
90 (69.2%) 
15 (11.5%) 
65 (50.0%) 
10 (7.7%) 
Bruising 
77 (59.2%) 
7 (5.4%) 
44 (33.8%) 
26 (20.0%) 
Pain 
83 (63.8%) 
17 (13.1%) 
57 (43.8%) 
9 (6.9%) 
Itching 
33 (25.4%) 
10 (7.7%) 
19 (14.6%) 
4 (3.1%) 
Lumps/bumps 
75 (57.7%) 
14 (10.8%) 
44 (33.8%) 
17 (13.1%) 
Discoloration 
28 (21.5%) 
5 (3.8%) 
13 (10.0%) 
10 (7.7%) 
* Number of treated subjects returning diaries, combined for Period I and Period 
II data Percentages are based on the number of subjects returning diaries 
 
2. Physician-Diagnosed Adverse Events 
46/143 of the Bellafill and 16/50 of the Control subjects experienced at least one all cause 
(related and unrelated) Treatment-Emergent Adverse Event (TEAEs). TEAEs that 
occurred in ≥ 4% of the subjects (related and unrelated) (i.e., 51/143 of the Bellafill and 
12/50 of the Control subjects) are presented below in Table 4. 
 
Table 4: Treatment-Emergent AEs in ≥ 4% of the Subjects Sorted by System Organ Class (SOC) and 
Preferred Term 
System Organ 
Class Code 
Preferred Term 
(PT) 
Bellafill n=143* 
Control n=50 
Subjects 
Events 
Subjects 
Events 
General Disorders and 
Administration Site Conditions 
22 (15.4%) 
27 
1 (2.0%) 
1 
Burning sensation 
1 (0.7%) 
1 
0 (0.0) 
0 
Device breakage 
1 (0.7%) 
1 
0 (0.0) 
0 
Fatigue 
2 (1.4%) 
2 
0 (0.0) 
0 
Injection site bruising 
3 (2.1%) 
3 
0 (0.0) 
0 
Implant site mass 
1 (0.7%) 
1 
0 (0.0) 
0 
Injection site discoloration 
1 (0.7%) 
1 
0 (0.0) 
0 
Injection site pain 
3 (2.1%) 
3 
0 (0.0) 
0 
Injection site reactions 
6 (4.2%) 
6 
0 (0.0) 
0 
Pruritus 
1 (0.7%) 
1 
0 (0.0) 
0 
Swelling 
3 (2.1%) 
3 
0 (0.0) 
0 
Tenderness 
5 (3.5%) 
5 
1 (2.0%) 
1 
Infections and Infestations 
14 (9.8%) 
16 
4 (8.0%) 
6 
Bacterial infection 
1 (0.7%) 
1 
0 (0.0) 
0 
Bronchitis 
0 (0.0) 
0 
1 (2.0%) 
1 
Ear infection 
1 (0.7%) 
1 
0 (0.0) 
0 
Hordeolum 
1 (0.7%) 
1 
0 (0.0) 
0 
Influenza 
1 (0.7%) 
1 
0 (0.0) 
0 
Influenza-like illness 
2 (1.4%) 
2 
2 (4.0%) 
3 
Meningitis 
1 (0.7%) 
1 
0 (0.0) 
0 
Nasopharyngitis 
4 (2.8%) 
4 
0 (0.0) 
0 
Oral infection 
0 (0.0) 
0 
1 (2.0%) 
1 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 45 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
Pharyngitis 
1 (0.7%) 
1 
0 (0.0) 
0 
Pharyngitis streptococcal 
1 (0.7%) 
1 
1 (2.0) 
1 
Sinusitis 
2 (1.4%) 
2 
0 (0.0) 
0 
Skin papilloma 
1 (0.7%) 
1 
0 (0.0) 
0 
Musculoskeletal and 
Connective Tissue Disorders 
5 (3.5%) 
5 
5 (10.0%) 
5 
Arthralgia 
2 (1.4%) 
2 
0 (0.0) 
0 
Back pain 
2 (1.4%) 
2 
2 (4.0%) 
2 
Hand fracture 
0 (0.0) 
0 
1 (2.0%) 
1 
Pain in extremity 
1 (0.7%) 
1 
0 (0.0) 
0 
Tendonitis 
0 (0.0) 
0 
1 (2.0%) 
1 
Wrist fracture 
0 (0.0) 
0 
1 (2.0%) 
1 
Skin and Subcutaneous Tissue 
Disorders 
10 (6.9%) 
15 
2 (4.0%) 
2 
Acne 
1 (0.7%) 
1 
0 (0.0) 
0 
Actinic keratosis 
1 (0.7%) 
1 
0 (0.0) 
0 
Dermatitis atopic 
1 (0.7%) 
1 
0 (0.0) 
0 
Dermatitis contact 
2 (1.4%) 
2 
0 (0.0) 
0 
Erythema 
1 (0.7%) 
1 
0 (0.0) 
0 
Herpes Zoster 
1 (0.7%) 
1 
0 (0.0) 
0 
Papule 
1 (0.7%) 
1 
1 (2.0%) 
1 
Rash 
2 (1.4%) 
4 
0 (0.0) 
0 
Seborrhoeic dermatitis 
1 (0.7%) 
1 
0 (0.0) 
0 
Squamous cell carcinoma of skin 
1 (0.7%) 
1 
0 (0.0) 
0 
Urticaria 
1 (0.7%) 
1 
1 (2.0%) 
1 
* n=143 is based on 97 subjects treated with Bellafill from Study Period I and 46 Period II Control 
subjects that crossed over and were treated with Bellafill 
 
Five serious adverse events (SAEs) were noted during the study; cholecystitis, 
lower-back nerve impingement, recurrence of breast cancer, West Nile meningitis 
and exacerbation of depression. None were deemed related to study treatment. There 
were no deaths during the study. 
 
Adverse events of special interest were followed separately for the study. These 
included hyper and hypopigmentation, hypertrophic scarring or keloid formation and 
the appearance of granulomas. None of these adverse events were reported. 
 
Fourteen (14) Bellafill and no Control subjects experienced treatment-related adverse 
events (TRAEs). Twelve (12) adverse events were mild, one (1) case of injection site 
reaction was moderate in severity, and one (1) injection site bruising was severe in 
intensity. Eleven (11) events resolved and three (3) cases of injection site reaction 
(lumpiness directly after injection) persisted throughout the study. Two (2) of these 
events were deemed by the investigator to be mild and one event was deemed to be of 
moderate severity. All treatment-related adverse events (TRAEs) reported in Bellafill 
subjects by severity and duration are presented in Table 5 and 6, respectively. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 46 of 60 
(v1.0; 28-Aug-2015) 
 
 
Table 5: Summary of TRAE (by Severity) 
 
System Organ Class/Preferred 
Term 
Subject (n=143) 
Events 
Any TRAE 
14 (9.8%) 
14 
Mild 
12 (8.4%) 
12 
Moderate 
1 (0.7%) 
1 
Severe 
1 (0.7%) 
1 
General Disorders and Administration Site Conditions 
Implant site mass 
1 (0.7%) 
1 
Mild 
1 (0.7%) 
1 
Moderate 
0 
0 
Severe 
0 
0 
Injection site pain 
3 (2.1%) 
3 
Mild 
3 (2.1%) 
3 
Moderate 
0 
0 
Severe 
0 
0 
Injection site reactions 
(i.e., lumpiness and papule 
formation) 
4 (2.8%) 
4 
Mild 
3 (2.1%) 
3 
Moderate 
1 (0.7%) 
1 
Severe 
0 
0 
Swelling 
1 (0.7%) 
1 
Mild 
1 (0.7%) 
1 
Moderate 
0 
0 
Severe 
0 
0 
Injection site bruising 
3 (2.1%) 
3 
Mild 
2 (1.4%) 
2 
Moderate 
0 
0 
Severe 
1 (0.7%) 
1 
Tenderness 
1 (0.7%) 
1 
Mild 
1 (0.7%) 
1 
Moderate 
0 
0 
Severe 
0 
0 
Skin and Subcutaneous Tissue Disorders 
Acne 
1 (0.7%) 
1 
Mild 
1 (0.7%) 
1 
Moderate 
0 
0 
Severe 
0 
0 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 47 of 60 
(v1.0; 28-Aug-2015) 
 
 
Table 6: Summary of TRAE (by Duration) 
SOC/PT 
Subject (n=143) Events 
Any TRAE 
n 
14 
14 
Mean # days (SD) 
30.8 (53.8) 
Median (min max) 
16 (1,180) 
General Disorders and Administration Site Conditions 
Implant site mass 
n 
1 
1 
Mean # days (SD) 
180 (0) 
Median (min max) 
180 (180,180) 
Injection site pain 
n 
3 
3 
Mean # days (SD) 
3.7 (1.5) 
Median (min max) 
4 (2,5) 
Injection site 
reactions (i.e., 
lumpiness and papule 
n 
4* 
4 
Mean # days (SD) 
76 (0) 
Median (min max) 
76 (76,76) 
Swelling 
n 
1 
1 
Mean # days (SD) 
1 (0) 
Median (min max) 
1 (1,1) 
Injection site bruising 
n 
3 
3 
Mean # days (SD) 
17.3 (0.6) 
Median (min max) 
17 (17,18) 
Tenderness 
n 
1 
1 
Mean # days (SD) 
3 (0) 
Median (min max) 
3 (3,3) 
Skin and Subcutaneous Tissue Disorders 
Acne 
n 
1 
1 
Mean # days (SD) 
16 (0) 
Median (min max) 
16 (16,16) 
*Data doesn’t include 3 subjects each with 1 unresolved event 
 
c) US 5-Year Post Approval Study (PAS001-Study P521-01) 
In agreement with FDA, Suneva Medical conducted a 5-year prospective study of 
Bellafill as an injectable implant for the correction of nasolabial folds (NLF). 
The primary objectives were to determine the incidence of granuloma formation and the 
incidence of adverse events at each follow-up period. The secondary objective was to 
determine the subject’s assessment of satisfaction using a five-point scale at each follow- 
up visit over the 5 year time period. 
 
This was a multi-center (23 sites), open-label study in which one thousand and eight 
(1008) subjects were followed for a five-year period after their completion of NLF 
correction with Bellafill. Treatments were administered according to the approved 
labeling for the Bellafill NLF indication. Subjects underwent up to three injection 
sessions over 6 weeks as needed to obtain the best possible correction. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 48 of 60 
(v1.0; 28-Aug-2015) 
 
 
Follow-up for AEs and satisfaction data was completed by mail or telephone 
questionnaire survey at 6, 12, and 18 months, and 2, 3 and 4 years post-treatment. 
Subjects were seen and examined in person at the 5 year post-treatment visit. If the 
questionnaire responses submitted at any timepoint indicated a potential adverse event 
in the treatment area and/or the face, the subjects were asked to return to the study site 
for evaluation. 
 
Adverse events reported by subjects were confirmed and adjudicated by the 
investigators. Any event that an Investigator thought might potentially be a 
granulomatous lesion was biopsied and sent to an independent pathology lab for 
evaluation and diagnosis. 
 
Primary Endpoints (safety): (1) Incidence of clinically identified and histologically 
confirmed granulomas tabulated by event and by subject; (2) incidence of serious 
unanticipated AEs stratified by severity and relation to treatment and tabulated by event 
and by subject; (3) incidence of anticipated AEs categorized as granulomas, serious 
unanticipated AEs, and AEs tabulated by event and within each study period. 
 
Results confirmed both the short and long term (5 year) safety of Bellafill, as no device- 
related serious adverse events (SAEs) or unanticipated AEs were noted and the general 
adverse event profile was similar to prior NLF studies. 
 
A total of 887 AEs were reported among 416 of the 1008 treated subjects. A total of 101 
SAEs were reported among 75 treated subjects; none of these SAEs were considered 
device-related, and all were unanticipated. Of these 101 serious adverse events the 
majority were moderate to severe (86). The most commonly reported SAEs were “other 
systemic complications (46)” and “other local complications (43)” non device–related 
SAEs. 
 
A total of 177 device-related AEs among 118 treated subjects were observed. Of the 
177 treatment-related adverse events, the majority (131, 74%) were mild in severity. 
Forty-two (24%) of these related events were moderate in severity and four (2.0%) 
were considered severe. The most commonly reported device related adverse events 
were “lumpiness at the injection site” (29%) followed by “redness” (11%) see 
Table 7. 
 
The duration of device related adverse events is provided in Table 8. Most of the 
device related adverse events were resolved during the study period. Thirty two related 
adverse events (18%) were deemed to be ongoing. The number of device related 
adverse events observed within the first month, 1-6 months, and beyond 6 months were 
comparable. The most common ongoing device related event was “lumpiness at the 
injection site” (12, 7%). 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 49 of 60 
(v1.0; 28-Aug-2015) 
 
 
TABLE 7: Summary of Device-Related Adverse Event Severity (N=1008) 
 
AE Category 
Device-Related AE Severity 
Total 
Mild 
Moderate 
Severe 
Lumpiness at injection site 
46 
6 
0 
52 
Redness 
19 
1 
0 
20 
Other local complications 
13 
5 
0 
18 
Granuloma or enlargement of the implant 
7 
9 
2 
181 
Swelling 
8 
8 
1 
17 
Pain/ Tenderness 
10 
4 
0 
14 
Skin blanching or discoloration at injection site 
6 
3 
0 
9 
Increased sensitivity 
8 
0 
0 
8 
Itching and/or burning 
7 
0 
0 
7 
Other systemic complications 
0 
4 
0 
4 
Hardness at the injection area 
1 
1 
1 
3 
Rash 
2 
0 
0 
2 
Scab and/or Scar 
0 
1 
0 
1 
Recurrence of pre-existing Herpes labialis 
1 
0 
0 
1 
Tingling, numbness, temp pain in various 
areas of the body 
1 
0 
0 
1 
Stinging 
1 
0 
0 
1 
Small veins in the implant area 
1 
0 
0 
1 
Total 
131 
42 
4 
177 
1These 18 events occurred in 17 subjects. One subject had bilateral, biopsy-proven granuloma 
 
Table 8: Summary of Device-Related Adverse Event by Duration 
AE Category 
Device-Related AE by Duration 
Total 
≤ 30 
days 
31-180 
days 
>180 
days 
On 
Going 
Missing1 
Other systemic complications 
2 
0 
1 
1 
0 
4 
Other local complications 
5 
5 
3 
4 
1 
18 
Lumpiness at injection site 
8 
11 
19 
12 
2 
52 
Redness 
7 
6 
6 
1 
0 
20 
Swelling 
12 
2 
2 
1 
0 
17 
Granuloma or enlargement 
of the implant 
0 
3 
5 
10 
0 
182 
Pain/ Tenderness 
6 
2 
6 
0 
0 
14 
Itching and/or burning 
2 
2 
2 
1 
0 
7 
Increased sensitivity 
1 
2 
5 
0 
0 
8 
Skin blanching or 
discoloration at injection 
5 
2 
1 
1 
0 
9 
Rash 
1 
0 
1 
0 
0 
2 
Hardness at the injection area 
0 
1 
1 
1 
0 
3 
Scab and/or Scar 
0 
1 
0 
0 
0 
1 
Recurrence of pre- 
existing Herpes labialis 
1 
0 
0 
0 
0 
1 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 50 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
Tingling, numbness, temp 
pain in various areas of 
the body 
1 
0 
0 
0 
0 
1 
Stinging 
1 
0 
0 
0 
0 
1 
Small veins in the 
implant area 
0 
0 
1 
0 
0 
1 
Total 
52 
37 
53 
32 
3 
177 
1 AEs with missing durations. 
2 These 18 events occurred in 17 subjects. One subject had bilateral, biopsy-provengranuloma 
 
Granulomas were encountered in 17 of 1008 subjects (1.69%). All of these cases were 
considered at least possibly related to the treatment; however, none were identified as 
SAEs. The majority of these cases were assessed as mild or moderate in severity by the 
investigator (15/17) and typically responded to medical therapy. Eight of seventeen 
(8/17) cases resolved during the course of the study, 8/17 showed improvement by study 
exit and were still being treated at the time of study exit, and a single lesion remaining 
stable at study exit, although improved from the time of diagnosis (See Table 9). 
 
TABLE 9: The Time to Onset and Duration of Granuloma Formation in Bellafill Patients 
(N=1008) 
 
Months from Last 
Treatment to Onset 
Date 
Duration 
(Months) 
Status at Study 
Exit 
5 
Ongoing 
No change (stable) 
10 
3 
Resolved 
11 
9 
Resolved 
12 
3 
Resolved 
21 
8 
Resolved 
22 
4 
Resolved 
28 
Ongoing 
Improved 
29 
Ongoing 
Improved 
35 
Ongoing 
Improved 
35 
21 
Resolved 
35 
16 
Resolved 
37 
Ongoing 
Improved 
39 
Ongoing 
Improved 
41 
18 
Resolved 
42 
Ongoing 
Improved 
57 
Ongoing 
Improved 
61 
Ongoing 
Improved 
 
POST-MARKETING SURVEILLANCE 
 
Since product approval for the correction of nasolabial folds, the adverse events 
received via Bellafill post-marketing surveillance in on-label or off-label settings have 
been infrequent. 
Those events that were reported in five or more instances include (in order of 
decreasing frequency reported) lumps/bumps, swelling, nodules, bruising, granuloma, 
redness, and reported allergic reactions. Time to onset for these events ranged from 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 51 of 60 
(v1.0; 28-Aug-2015) 
 
 
immediate to three-and- a-half years post-injection. The majority of the events (when 
severity was reported) were mild in severity and no events were characterized as 
serious. Outcomes for these events ranged from resolution to ongoing at the time of last 
contact. The treatments for these events included massage, ice packs, warm compresses, 
antibiotics, antihistamines, various energy treatments, oral and intralesional steroids, 
and device excision. 
 
Adverse events possibly related to intravascular injection have been reported. 
Symptoms ranged from possible skin discoloration to bumps to skin necrosis. Time of 
onset (when known) ranged from the day of injection to 3 days post treatment. The 
majority of the intravascular injection events were mild in severity and no events were 
reported as serious. Treatments included nitroglycerin paste, aspirin, and warm 
compresses. These events resolved or were resolving within one month after onset. 
 
A single case of blindness was reported as a Medical Device Report (MDR) after 
Bellafill injection. The patient was injected in the right canthal area (periorbital), and 
experienced immediate onset of loss of vision in the right eye. Treatments included 
IV saline, direct pressure release in the anterior chamber of the eye, and treatment in 
a hyperbaric oxygen chamber. The patient’s vision did not return. In this patient 
case, periorbital injection of Bellafill was outside the recommended Indications for 
Use (see Warnings section). 
 
Adverse reactions should be reported to Suneva Medical, Inc., at 1-858-550-9999. 
 
U.S. CLINICAL TRIALS 
a) CONTROLLED NASOLABIAL FOLD TRIAL 
A prospective, multi-center, double-masked, randomized trial compared Bellafill and a 
commercially available collagen implant for the treatment of soft tissue defects of the 
face. A total of 251 (i.e., 128 Bellafill and 123 Control) subjects were enrolled and the 
nasolabial folds of 212 (i.e., 108 Bellafill and 104 Control) subjects were treated. 
The primary effectiveness endpoint was a comparison of the cosmetic correction 
provided by Bellafill and Control treatments at the end of a 6-month period after 
injection, evaluated by means of a validated facial-fold assessment scale (FFA Scale) 
using standardized photographs as reference. The numerical values for the FFA Scale 
were: zero – no folds; one – folds just perceptible (i.e., ~0.1 mm); two – shallow folds 
with some defined edges (i.e., ~0.2 mm); three – moderately deep folds with some well- 
defined edges (i.e., ~0.5 mm); four – deep folds with most edges well defined and some 
redundant folds (i.e., ~1.0 mm) and five – very deep folds with most edges well defined 
and some redundant folds (i.e., ~2.0 mm). Comparisons to the reference photos were 
made at pre-treatment and at each follow-up visit. Safety was evaluated by comparing 
the incidence and severity of clinical events during and for 12 months after treatment 
completion. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 52 of 60 
(v1.0; 28-Aug-2015) 
 
 
Subject and Baseline Characteristics are presented in Table 10. 
 
Table 10: Subject and Baseline Characteristics 
 
Demographic 
Bellafill 
(n=128) 
Control 
(n=123) 
Gender 
Male 
11 (8.6%) 
11 (8.9%) 
Female 
117 (91.4%) 
112 (91.1%) 
Age, years 
Mean 
53.2 
51.2 
Range 
28–82 
29–78 
Ethnicity 
Caucasian 
100 (78.1%) 
101 (82.1%) 
Hispanic 
21 (16.4%) 
20 (16.3%) 
Asian 
1 (0.8%) 
1 (0.8%) 
Other1 
6 (4.7%) 
1 (0.8%) 
Facial Area Treated 
Nasolabial Folds 
108 (84.4%) 
104 (84.6%) 
Wrinkle Severity 
Mean Value 
Mean Value 
Nasolabial Folds2 
1.74 
1.45 
1“Other” ethnicities, as reported by Bellafill subjects, were Mexican/Greek/English, Italian, 
Hispanic/Irish, American Indian, Native American, Middle Eastern. “Other” ethnicity, as reported 
by a Control subject, was Persian. 
2Subjects in the Bellafill treated group had a higher baseline fold severity than those in the 
Control group. The difference was statistically significant (p=0.039). 
 
Results 
The mean improvement in nasolabial fold wrinkle severity, as characterized by the 
masked observers, for subjects from before treatment to 6 months after completion of 
treatment was: Bellafill – 0.77 points, and Control – 0.00 points. The difference was 
statistically significant (p 
= < 0.001). 
 
Additional Analysis 
At 1 month after treatment, 0.75 points (Bellafill) and 0.74 points (Control) differences 
from baseline for nasolabial fold wrinkle severity were recorded. At 3 months after 
treatment, differences of 0.81 points (Bellafill) and 0.15 points (Control) were 
determined for nasolabial fold. At 12 months after treatment, a nasolabial wrinkle 
severity difference of 0.98 points (compared to baseline) was recorded for Bellafill 
subjects. No assessment of nasolabial fold wrinkle severity was performed at 12 months 
after treatment for Control subjects. 
The number of treatment sessions and volumes administered in nasolabial folds over the 
course of the study are displayed in Table 11 and 12, respectively. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 53 of 60 
(v1.0; 28-Aug-2015) 
 
 
Table 11: Mean Number of Treatment Sessions per Product 
Area 
Bellafill 
Control 
Nasolabial Folds 
2.28 (n=108) 
2.18 (n=104) 
 
Table 12: Mean Volume of Product Used per Side(Left/Right) 
Treatment Area 
Bellafill (cc) 
Control (cc) 
Nasolabial Folds 
0.82 (n=108) 
1.46 (n=104) 
 
b) OPEN-LABEL NASOLABIAL-FOLD STUDY 
This open-label, single-arm, multi-center study assessed the safety of Bellafill injections 
for the correction of soft-tissue defects of the face. 157 subjects were enrolled and 
monitored at 3, 6, and 12 months post-treatment. Approximately 80% (126/157) of 
subjects completed the 1-year study. The safety data collected in this study were included 
in Table 1. 
 
c) CONTROLLED ACNE SCAR STUDY 
A prospective, multi-center, randomized, double-blind, controlled trial assessing the 
effectiveness and safety of Bellafill for the correction of facial atrophic acne scars was 
conducted. A total of 147 (97 Bellafill and 50 Saline Control) subjects were enrolled 
and treated in the controlled phase of the study. 
The primary effectiveness endpoint was a responder analysis in which the criteria for 
success at 6 months was defined as 50% or more of treated scars improving by 2 or 
more points, based on the blinded-investigator assessment utilizing the validated 4 point 
Acne Scar Rating Scale (ASRS). The objective was to show that Bellafill was superior 
to Control in treating acne scars. The ASRS (Table 13) is a four-point, static scale, 
ranging from minimal to severe, that relies on the depth of individual scars for severity 
assessment. 
 
Table 13: Acne Scar Rating Scale (ASRS) 
Score 
Description 
1 
Minimal – Depth up to 0.5mm. 
Visibility = Perceptible with tangential lighting 
2 
Mild – Depth >0.5mm to <1.5mm. 
Visibility = Moderately detectable with tangential lighting 
3 
Moderate – Depth = ≥1.5mm to <2.5mm. Visibility = 
Easily seen with tangential lighting 
4 
Severe – Depth = ≥2.5mm in depth. 
Visibility = Substantial shadowing with tangential lighting 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 54 of 60 
(v1.0; 28-Aug-2015) 
 
 
Subject and Baseline Characteristics are presented in Table 14. 
 
Table 14: Subject and Baseline Characteristics 
Demographic 
Bellafill (n=97) 
Control (n=50) 
Gender 
Male 
37 (38.1%) 
20 (40.0%) 
Female 
60 (61.9%) 
30 (60.0%) 
Age, years 
Mean 
44.6 
45.3 
Range 
21–67 
22–63 
Race 
Caucasian 
70 (72.2%) 
38 (76.0%) 
Black 
20 (20.6%) 
8 (16.0%) 
American Indian/Native Alaskan 
2 (2.1%) 
0 (0.0%) 
Native Hawaiian/Pacific Islander 
1 (1.0) 
0 (0.0%) 
Asian 
4 (4.1) 
4 (8.0%) 
Other 
0 (0.0%) 
0 (0.0%) 
Ethnicity 
Non-Hispanic 
77 (79.4%) 
37 (74.0%) 
Hispanic 
20 (20.6%) 
13 (26.0%) 
 
The number and severity of scars per subject are shown in Table 15. There were no 
differences between treatment groups regarding the number of qualifying scars or their 
severity. The median number of scars to be treated for each subject was 8.0 in each group 
(mean value shown below) with a median Acne Scar Rating Scale (ASRS) severity of 3.2 
in each group. 
 
Table 15: Acne Scar Characteristics at Baseline 
Number and Severity of Scars 
Bellafill 
(n=97) 
Control (n=50) 
Number of 
qualified 
N 
97 
50 
Mean ± SD 
8.9 ± 4.6 
8.5 ± 3.7 
Mean scar severity 
N 
97 
50 
Mean ± SD 
3.3 ± 0.3 
3.3 ± 0.3 
Average volume/subject (mL) 
– Total 
N 
97 
50 
Mean ± SD 
1.50 ± 1.03 
2.61 ± 1.80 
Note: Mean ± standard deviation. 
 
Results 
The primary effectiveness endpoint was analyzed as a responder analysis, in which the 
criterion for success was defined as 50% or more of treated scars on a patient improved 
by two or more points on the ASRS at the 6 month visit (as evaluated by a live, blinded 
evaluator). The observed success rate at 6 months in the Bellafill group was 56/87 
(64%) and significantly higher (p=0.0005) than in the Control group 15/46 (33%). 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 55 of 60 
(v1.0; 28-Aug-2015) 
 
 
Bellafill was found to be effective in all Fitzpatrick skin types, and for male subjects as 
well as female subjects. 
 
A secondary effectiveness endpoint was a responder analysis (i.e., success was defined 
as 50% or more of treated scars on a patient improved by two or more points) 
determined via ASRS at each time point by a live, blinded evaluator. The observed 
success rates in unblinded assessments at 9 and 12 months for the Bellafill group were 
48/78 (61.5%) and 58/82 (70.7%). See Figure 1. 
 
Figure 1: Proportion (%) of Responders Assessed by the Blinded Evaluator 
Based on the Observed Estimate 
 
 
Bellafill Treatment 
26.9% 
60.0% 
66.7% 
62.4% 
64.4% 
61.5% 
70.7% 
Control Treatment 
18.8% 
33.3% 
40.9% 
35.7% 
32.6% 
NA 
NA 
 
Bellafill Responders / 
Number of Subjects 
25/93 
60/75 
54/81 
53/85 
56/87 
48/78 
58/82 
Control Responders / 
Number of Subjects 
9/48 
14/42 
18/44 
15/42 
15/46 
NA 
NA 
Additional Effectiveness Analyses 
In addition to assessing patient responder rates, the response rate of individual scars was 
also compared. In this analysis where scars with a greater-than or equal-to two-point 
improvement on the ASRS over baseline were considered responders, 442/789 (56.0%) 
of scars in the Bellafill group and 118/397 (29.7%) of scars in the Control group were 
judged as successes. 
Bellafill injections were superior to Control treatment at all study visits after the Week 4 
touch- up injection. 
Independent, masked review of photographs (IPR) from the Month 6 visit by three 
board- certified physicians revealed a higher ASRS response rate for Bellafill than 
Control subjects, but these rates were lower than those determined by live, blinded 
evaluators. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 56 of 60 
(v1.0; 28-Aug-2015) 
 
 
Subjects blinded to the treatment rated the overall degree of improvement in their treated 
scars using a five-point, non-validated Subject Global Aesthetic Improvement Scale 
(SGAIS) where 5 was “much improved”, 3 was “no change” and 1 was “much worse.” 
Seventy-seven percent (77.0%) of subjects (67/87) treated with Bellafill and forty-one 
percent (41.3%) treated with Control (19/46) reported improvement in their global 
appearance at 6 months after their injection. Subjects who were treated with Bellafill 
continued to report improvement in their global appearance in an unblinded assessment 
at Month 9 (84.6%) 66/78 and at Month 12 (83.1%) 69/83. 
 
BENEFIT / RISK CONCLUSIONS 
The benefits as determined by the improvements seen on the Acne Scar Rating Scale 
and patient satisfaction scale as well as the risks as assessed from short-term adverse 
outcomes seen after injection and rare late adverse events, are sufficiently well 
understood for patients to make informed decisions about device use. 
 
d.) US 5-Year Post Approval Study (PAS001-Study P521-01) 
Total number of Enrolled Study Sites and Subjects, Follow-up Rate: This was an 
open label uncontrolled study in which 23 sites enrolled 1008 subjects with a 
completion rate of 87% at the end of the 5-year study. The primary objectives were to 
determine the incidence of granuloma formation and the incidence of adverse events at 
each follow-up period. The secondary objective was to determine the subject’s 
assessment of satisfaction using a five-point scale at each follow-up visit over the 5 year 
time period.” 
 
The Effectiveness Endpoint was based on: Subject satisfaction using a 5-point scale, 
where 1 = very satisfied, 2 = satisfied, 3 = somewhat satisfied, 4 = dissatisfied and 5 = 
very dissatisfied. 
 
Study Visits and Length of Follow-up: After treatment, subsequent follow-up was 
conducted by mail or telephone questionnaire survey at 6, 12, and 18 months, and 2, 3 
and 4 years post- treatment. Subjects were seen and examined in person at 5 years post- 
treatment visit. 
 
The study population is shown in Table 16 below. The population enrolled is typical of 
individuals seeking correction of NLFs in current clinical practice. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 57 of 60 
(v1.0; 28-Aug-2015) 
 
 
Table 16: Demographic Summary 
CHARACTERISTIC 
N (%) 
N=1008 
GENDER 
Male 
112 (11.1%) 
Female 
896 (88.9%) 
ETHNICITY 
Hispanic or Latino 
138 (13.7%) 
Not Hispanic or Latino 
870 (86.3%) 
RACE1 
White 
886 (87.9%) 
Black 
54 (5.4%) 
Asian 
12 (1.2%) 
American Indian/Native Alaskan 
11 (1.1%) 
Native Hawaiian/Pacific Islander 
Other2 
2 (0.2%) 
54 (5.4%) 
AGE (yrs.) 
Mean 
53.76 
Range 
22–86 
1 Subjects were permitted to report more than one race, therefore the total number of subjects 
exceeds the number of subjects in the study (N=1008). 
2 'Other' race responses include the following: 
Argentinian, Black / Korean, Hispanic or Latino, Hispanic- Portuguese, Indian, Iranian, Latino, 
Mexican, Mexican American, Portuguese, Puerto Rican, Spanish (Spain) 
 
3. Results: Effectiveness – Subject Satisfaction 
Based on subject assessment of satisfaction (using an unbalanced and unvalidated 
scale), patients reported satisfaction with Bellafill treatment throughout the entire study. 
One year after the final treatment the mean subject satisfaction rating was 1.80 (where 
1= very satisfied and 2= satisfied). At 5 years after the last treatment 83% of subjects 
were either very satisfied or satisfied with their treatment outcome and the mean 
Satisfaction score was 1.70. 
 
e) COLLAGEN IMMUNOREACTIVITY 
All subjects were required to have a Skin Test prior to being considered for injection 
with Bellafill. 
Results of the Skin Tests – In the randomized NLF study, there were no positive Skin 
Tests in the 128 patients first randomized to receive Bellafill treatment or the 106 
Control subjects who elected to receive Bellafill injections in the crossover cohort. Of 
the 141 subjects who received the collagen Control Skin Test, 6 had a positive Skin Test 
and were excluded from the study. 
Serum IgG – In the randomized NLF study, 4 Bellafill and 2 Control subjects were not 
treated because they displayed abnormal baseline serum IgG levels against collagen 
during screening. One subject in the Bellafill group transitioned from a normal IgG 
level before administration of the Skin Test to a value above the normal range at 1 
month after treatment. This subject’s IgG levels returned to the normal range by 3 
months after treatment. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 58 of 60 
(v1.0; 28-Aug-2015) 
 
 
Acne Scar Study: 175 subjects received the Bellafill Skin Test. Three subjects (1.7%) 
demonstrated a positive Skin Test, and were excluded. 
5- Year Post Approval Study: 1211 subjects received the Bellafill Skin Test. Eight 
subjects (0.7%) demonstrated a positive Skin Test, and were excluded. 
 
INDIVIDUALIZATION OF TREATMENT 
A complete medical history should be obtained to determine whether the patient is an 
appropriate candidate for treatment with Bellafill. 
 
HOW SUPPLIED 
Bellafill is an aseptic product that is required to pass a USP sterility test before release. 
It is supplied in a sealed tray containing individual treatment syringes with sterile 
needles for single patient use, packaged in a box. Each syringe contains: 20% 
polymethylmethacrylate microspheres and 80% bovine collagen solution containing 
3.5% bovine collagen, 2.7% phosphate buffer, 0.9% sodium chloride, 0.3% lidocaine 
hydrochloride, and 92.6% water for injection. 
The tray lid and tip of each individual syringe is sealed with a tamper evident cover. Do 
not use if the tamper evidence cover is broken or removed. Do Not Sterilize. 
 
IMMUNOGENICITY TEST PROCEDURE 
Four (4) weeks prior to treatment, patients will be given a 0.1cc test injection of Bellafill 
skin test material intradermally in the volar forearm, to determine a patient's sensitivity 
to the treatment material. For a complete discussion of the Bellafill Skin Test, refer to 
the Instructions for Use supplied with test syringes. 
 
Test Interpretation 
The patient should observe the test site daily during the 4-week test period and notify 
the physician immediately if any effects indicative of a positive or equivocal response 
are observed or if systemic effects are experienced. A Bellafill Skin Test Results Card 
should be provided to the patient at the time of the Skin Test to help the patient assess 
the test site. 
 
Positive Response 
A positive response consists of erythema of any degree, induration, tenderness, and 
swelling, with or without pruritus, which can appear immediately following 
implantation and persists for more than 24 hours or appears more than 24 hours 
following implantation for any length of time. 
 
Equivocal Response 
An equivocal response is one in which there is no localized skin reaction, but the patient 
does elicit a possible systemic reaction such as a rash, arthralgia (aching joints), or 
myalgia (aching muscles) that occurs at any time during the 4-week observation period. 
If an equivocal response is observed, a second injection in the opposite arm is required, 
with observation for an additional 4 weeks. Patients demonstrating a positive or 
equivocal response in this second test should not be treated. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 59 of 60 
(v1.0; 28-Aug-2015) 
 
 
 
DIRECTIONS FOR USE 
Bellafill is indicated for the correction of nasolabial folds and moderate to severe, 
atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. 
1. Prior to treatment with Bellafill, the results of the Skin Test must be carefully 
evaluated; the patient must not have a response to the required Bellafill Skin Test. 
For a complete discussion of the Bellafill Skin Test, refer to the Instructions for 
Use supplied with Skin Test syringes. 
2. Prior to treatment with Bellafill, the patient should be fully informed of the 
indications, contraindications, warnings, precautions, treatment responses, 
adverse reactions, and method of administration. Patients also should be 
advised that supplemental touch-up treatments might be required to achieve 
correction. 
3. A complete medical history should be obtained to determine whether the 
patient is an appropriate candidate for treatment with Bellafill. 
4. The patient’s soft-tissue contour deficiencies should be characterized with 
regard to etiology, distensibility, and depth of lesion. Pretreatment photographs 
are recommended. 
5. Scars selected for treatment should be atrophic distensible scars. 
6. The Bellafill syringe must be brought to room temperature before injection. 
7. After ensuring that the patient has thoroughly washed the treatment area with 
soap and water, the area should be cleaned with alcohol or other antiseptic. 
8. Bellafill is implanted through a 26 G needle. Best results with Bellafill are achieved 
in defects requiring deep dermal implant placement and not into the subcutaneous 
fat. The rate and degree of correction in the implanted area varies with patient, 
treatment site, and plane of implant placement. Correction should be conservative 
during initial treatment. 
9. Before injecting the patient, depress the syringe plunger until Bellafill is visible at 
the tip of the needle. 
10. The best cosmetic result for NLFs can be achieved by a standard linear threading 
technique moving the needle back and forth beneath the skin being treated and 
maintaining constant injection pressure while withdrawing the needle (retrograde 
liner threading). Injection for acne scar can use both the retrograde linear threading 
and serial puncture techniques. The injection pressure is correct if the implant 
flows slowly and evenly, without great exertion. This technique forms a support 
structure beneath the skin to prevent further wrinkling and/or to maintain the scar 
correction. 
11. If needles become occluded or dull during a treatment session, 
replacement may be necessary. 
12. Gentle massage of the skin with the fingertips may facilitate even distribution of 
Bellafill immediately after implant placement. 

Bellafill
® Acne Scar Trial 
Protocol # SUN-15-04 
Suneva Medical, Inc. 
CONFIDENTIAL 
Page 60 of 60 
(v1.0; 28-Aug-2015) 
 
 
13. The area and the borders of Bellafill injection should be recorded on an illustration 
of a face for later comparison. 
14. The physician should instruct the patient to report to him or her any evidence of 
adverse texture change in the surrounding treatment site. Other problems 
possibly associated with the use of Bellafill should be promptly brought to the 
attention of the physician. 
15. The syringe and any unused material should be discarded after a single treatment 
visit. 
16. Correction should be limited to no more than 100% of the skin defect during 
treatment. One or two touch-up implantations at intervals of at least 2 weeks may 
be required to achieve the desired effect. The interval at which touch-up 
implantations are needed depends on the nature of the defect, the amount of 
implant injected, the site of placement, and the dynamics at the corrected sites. 
 
STORAGE DIRECTIONS 
Bellafill should be stored at standard domestic refrigerator temperatures. DO NOT 
FREEZE. 
Bellafill has an off-white appearance. In the event that the content of a syringe shows 
signs of separation and/or is clear (like water), do not use the syringe and notify Suneva 
Medical immediately. In the United States or Canada, call toll-free 844-235-5234. 
Outside of the United States or Canada call ++1-858-550-9999. 
 
PATIENT COUNSELING 
Patients considering treatment with Bellafill should be provided with the patient 
labeling, which is available by contacting Suneva Medical. Patients should be told that 
more than one treatment session might be required to achieve the desired correction. 
 
ORDERING 
To place an order, contact Suneva Medical, Inc. In the United States or Canada, call 
toll-free 844-235-5234. Outside of the United States or Canada call ++1-858-550- 
9999. Orders may also be sent by fax to 858-550-9997 or email to 
orders@sunevamedical.com. 
 
SUNEVA MEDICAL, Inc. 
5870 Pacific Center 
Blvd. San Diego, CA 
92121 United States 
of America 
 
Toll-free Phone in the US or Canada 844-235-5234 Outside the US or Canada Phone ++1-858-550-9999 
Fax 858-550-9997 
customersupport@sunevamedical.com www.sunevamedical.com www.bellafill.com 
Part Number: 7220 REV01 (Date 08/2015)